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ABSTRACT
Stochastic models are developed to capture the inherent stochasticity of the biochemical
networks associated to many biological processes. The objective of the present thesis is to
present a detailed picture of stochastic approach for the mathematical modeling of eukaryotic
cell cycle, to demonstrate an important application of such model in chemotherapy and to present
a methodology for selecting the model parameters. The stochastic cell cycle model, developed
using stochastic chemical kinetics approach, leads to the formation of an infinite dimensional
differential equation in probabilities of system being in a specific state. Using Monte Carlo
simulations of this model, dynamics of populations of eukaryotic cells such as yeasts or
mammalian cells are obtained. Simulations are stochastic in nature and therefore exhibit
variability among cells that is similar to the variability observed in natural populations. The
model‟s capability to predict heterogeneities in cell populations is used as a basis to implement it
in a chemotherapic modeling framework to demonstrate how the model can be used to assist in
the drug development stage by investigating drug administration strategies that can have
different killing effect on cancer cells and healthy cells.
Finally, basic cell cycle model is refined in a systematic way to make it more suitable for
describing the population characteristics of budding yeast. Selection of model parameters using
an evolutionary optimization strategy referred to as insilico evolution is described. The benefits
of this approach lie in the fact that it generates an initial guess of reasonable set of parameters
which in turn can be used in the least squares fitting of model to the steady state distributions
obtained from flow cytometry measurements. The Insilco evolution algorithm serves as a tool for
sensitivity analysis of the model parameters and leads to a synergistic approach of model and
experiments guiding each other.
xi

To conclude, the stochastic model based on single cell kinetics will be useful for
predicting the population distribution on whole organism level. Such models find applications in
wide areas of biological and biomedical applications. Evolutionary optimization strategies can be
used in parameter estimation methods based on steady state distributions.

xii

CHAPTER 1. INTRODUCTION
1.1 Eukaryotic Cell Cycle - Overview
Cell cycle is an orderly sequence of events by which cells replicate and divide into two
daughter cells with identical genetic material. The eukaryotic cell cycle is divided into four
different phases: gap phase -G1, synthesis (S) phase, gap phase -G2 and mitosis (M) phase. DNA
is replicated once per cell cycle in the S phase, duplicated chromosomes are separated and
moved to two opposite poles of mitotic spindle in the M phase. S and M phases are separated in
time by the gaps G1, G2. G1 precedes S phase and prepares cell for DNA replication; G2
precedes M phase and prepares cell for division. M phase is separated into five sub phases:
prophase - the extended duplicated genome condenses into chromosomes, which are highly
ordered structures and metabolic activity is reduced; prometaphase - the nuclear envelope breaks
and microtubules elongate from centromeres; metaphase - condensed chromosomes align
properly in the metaphase plane; anaphase - the duplicated chromosomes are separated into two
identical parts and move towards the opposite poles of the spindle; telophase - the chromosomes
decondensate, metabolic activity is restored, and the nuclear envelope is reconstructed. The cell
cycle ends with cytokinesis where the cell divides into two each with same copies of genetic
material. The duration of the total cell cycle varies for different species and for different tissues
in the same species.
Cell cycle has surveillance mechanisms that control the progress of cell through the four
phases and ensure the crucial processes of replication and division are performed with high
fidelity. These are called checkpoint controls which include both internal and external control
mechanisms. The internal mechanisms monitor the timely completion of critical cell cycle events
in proper order. External mechanisms control the progress of the cell cycle mainly in response to
1

three important events – DNA damage, replication blocks and mitotic spindle damage. Main
sources of DNA damage are environmental agents - genotoxic chemicals, UV and ionizing
radiation; highly reactive free radicals, by products of cellular metabolism; cell physiological
conditions that disintegrate the chemical bonds in DNA. These damages occur as single strand
breaks (SSBs), double strand breaks (DSBs), point mutations. Replication blocks occur during
DNA synthesis due to insufficient nucleotides and proteins or lesions on the DNA templates
halting synthesis of DNA strands. Inactivation or under-expression of the proteins involved in
the spindle formation causing misalignment of chromosomes resulting in mitotic spindle defects.
Checkpoints not only detect DNA damage and replication blocks, but also form an
integral part of multifaceted network of repair pathways that arrest the cell cycle progression to
allow sufficient time for repair, initiate the transcription of proteins involved in repair and
apoptosis or programmed cell death. Apoptosis occurs in multi-cellular organisms like mammals
to prevent the defective cell from harming the whole organism when the damage is too severe to
repair. A variety of proteins play crucial roles in DNA damage response pathways at various
stages by sensing the defects in cell cycle, transferring these signals to activate or transcribe
effector-proteins which carry out the corrective actions. Also, if there are spindle defects, cell is
arrested in the metaphase to allow time for related proteins to align the chromosomes properly.
Although there are differences in the number of molecules involved in the cell cycle
control system (CCCS) that regulates the eukaryotic cell cycle of different species, it is wellpreserved through the evolutionary history and all eukaryotes share similar set of key compounds
and interactions. The core of CCCS is a special group of enzymes called cyclin-dependent
kinases (Cdks). Cdks are maintained at constant level throughout the cell cycle and are in their
active state only when bound to cyclins. A variety of cyclins are synthesized during different
2

phases of cell cycle progression and their Cdk/cyclin complexes control the transition between
the phases. Cyclin levels are maintained by controlled proteolysis and transcription, two
regulatory processes that are important for cell cycle progression. If DNA damage is detected, or
if the cell growth is not sufficient to have synthesized required amounts of cyclins, the cell cycle
will be arrested in G1 phase. Cell enters into M-phase from G2 only if the DNA replication is
complete and the duplicated chromosomes are properly attached to opposite poles of mitotic
spindle. The transition from metaphase to anaphase which drives the separation of chromosomal
spindle and exit of mitosis, occurs when M-phase Cdk/cyclin complexes phosphorylate anaphase
promoting complex (APC) that in turn causes the proteolytic degradation of cyclins and of
proteins that hold the sister chromatids (duplicated chromosomes) together. Cdks and APC are
antagonistic in nature - the activated Cdk/cyclin activates conversion of APC to its inactive form
while active APC inactivates the Cdks by promoting the degradation of cyclins and the activation
of Cdk-inhibitors (CKIs).
1.2 Significance of Studying the Cell Cycle
Excellent reviews on the cell cycle regulation and its significance are presented in the
literature (Nurse, 2000; Tyers, 2004; Morgan, 2006). All the living organisms should maintain a
balance between the growth and division of cells for having control over cell size, for surviving
under different nutrient conditions and environment, and for performing all other key biological
processes. The imbalance between the growth and division is the key feature of tumors. Cell
cycles have great influence on neuronal, cardiovascular activities. Thus, many biological
functions are cell cycle dependent and understanding and controlling the cell cycle is highly
important in disease treatment. Inappropriate activation of apoptosis will lead to the killing of
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normal cells causing diseases like Alzheimer's. Inactivation of genes involved in apoptosis is
another cause of growing tumors.
Occurrence of many diseases is related to the defects in the cell cycle regulatory system.
Any defects to the genes involved in the cell cycle checkpoint pathways, repair mechanisms
result in chromosomal instability, mutations to crucial genes in the cell cycle growth regulation
and physiology leading to cancer, immunodeficiency and many disorders (Hanahan and
Weinberg, 2000). Cancer is caused by the genetic imbalance between the proliferation and
suppression mechanisms of normal cells resulting in their uncontrolled growth. Various types of
DNA damage discussed earlier, when unrepaired, will cause mutations to genes involved in the
mechanisms that control proliferation and cell death which will be carried to many generations.
These permanent mutations cause the activation of oncogenes that stimulate the proliferation or
protection against cell death and the inactivation of tumor suppressor genes which would
normally inhibit proliferation. This uncontrolled growth of cells leads to tumors in many cancer
cells.
Detailed study of cell cycle physiology helps in better understanding the biological
processes. Developmental biology is the study of the processes that give rise to tissues, organs
and organisms in specific shapes and patterns. These processes are controlled by biochemical
reactions which are closely related to the cell cycle. Cell migration which is a phenomenon
important in wound healing, tumor growth or apoptosis is influenced by two factors, cell cycle
phase and the cell size (Fuss et al., 2005).
1.3 Mathematical Modeling as a Tool for the Study of Cell Cycle
Earlier research in cellular processes involved identifying the important components of
the regulatory network and the interactions among each other. These interactions among the cell
4

cycle components occur at different spatial and temporal scales. With the advances in
experimental technology, experimental observations are possible to obtain at these different
scales. However, to better understand how these molecular interactions act in a system to
regulate the biological functions responsible for disease progression, development and other
cellular activities, a systems level analysis is required. Mathematical modeling provides a better
analysis tool for gaining system level understanding of the interactions of many components
acting in diverse ways.
Mathematical modeling can be used as a valuable tool in hypothesis testing. Hypotheses
are made about the mechanisms and functions of the cell cycle control system and a
mathematical model formed based on this hypothesis with proper assumptions will generate
predictions. The predictions from the model also will be helpful in estimating the key kinetic
parameters which are sometime difficult to measure. Based on the agreement of the model
predictions with the experimental observations, the hypothesis can be accepted, rejected or
modified to form a new hypothesis which gives directions to the design of new experiments. In
this way, mathematical modeling in synergism with the experiments will be useful as a tool for
identifying more realistic representations of the cell cycle molecular network and to achieve
better predictions of the biological phenomena.
Another application of mathematical modeling is to predict the behavior of cells subject
to different environmental conditions. The behavior of cells is generally measured in terms of the
concentrations of the cell cycle components or the growth of a cell population. One major
application is in the cancer chemotherapy, where mathematical model is used to predict the
response of cells to chemotherapic drugs. The predictive capabilities of mathematical models
help in reducing the financial burden of carrying out expensive experimental techniques.
5

1.4 Mathematical Models – Deterministic and Stochastic Approaches
Mathematical modeling involves converting the interactions among the proteins, enzymes
in the biochemical network to mathematical relationships which are mainly rates of synthesis and
degradation of proteins, association or dissociation reactions between two proteins. It is
important to know the mathematical form of these relationships. Mass action kinetics, MichaelisMenten kinetics or simple switch-like functions such as Goldbeter-Koshland function are some
of the forms used in variety of models. Two main approaches for modeling cellular networks are
deterministic and stochastic. The deterministic approach assumes average concentrations of the
cell cycle proteins and such approach will always give the same time trajectory of molecular
concentrations for specific parameters and initial system state expressed in terms of molecular
concentrations. The relationships among the reacting components are converted to differential
equations. Once the kinetic rate parameters are assigned and the initial conditions are specified,
the differential equations can be solved using numerical integration techniques to obtain the
concentration of various proteins with time. There are many models proposed in the literature
that follow this deterministic approach which are described in the literature review presented in
the next chapter.
The other approach is using stochastic modeling for describing the cellular processes
which are inherently stochastic. Molecular components of cellular processes often involve low
copy numbers and due to the complex interactions among these components, fluctuations in the
number of molecules become very important in deciding the outcome of the associated
biological processes. For example, stochastic events such as mutations play an important role in
the fate of a cell, which may convert to a cancer cell from a healthy cell. Cellular differentiation
is another stochastic phenomenon in which depending on the molecular state of the system, a
6

particular cell may convert to cell of any of different types of tissues.

Other biological

phenomena that are stochastic in nature include apoptosis and plaque formation. It is not always
possible to identify the complete interactions and external environmental effects on the
biochemical system. Stochastic models are developed to capture these stochastic phenomena.
1.5 Objective
Since the stochastic events occurring at the molecular level in a cell cycle network
influence the response of whole organism to external stimuli, a stochastic model developed based
on a cell cycle network, when accurately represented with the parameters will be helpful in
predicting the population responses to the stochastic events occurring at the molecular level. One
objective of the present work is to describe the development of a stochastic model of eukaryotic
cell cycle and present the scope of its practical application.
Budding yeast Saccharomyces cerevisiae is studied extensively for eukaryotic cell cycle
research. The yeast genome is well documented, and because yeast cells are unicellular they can
be cultured and genetically manipulated much more readily than mammalian cells. Additionally,
yeasts are eukaryotic and their gene regulation and biochemical pathways related to cell cycle
progression are similar to those found in higher organisms including humans. The model
development is based on the cell cycle network of budding yeast.
Stochastic models, even those that are simplified beyond biological reasonableness,
contain a large number of model parameters that must be determined for the model to be of
value. Stochastic models require data that captures fluctuations in concentrations at single cell
level for estimating the parameters. Another approach that can be employed to estimate the
parameters is by fitting the population distributions obtained from the model to the measured
distributions using least squares techniques. Another objective of the present work is to present a
7

strategy that can be used to identify the significance of different model parameters in model
fitting and to obtain reasonable values of the model parameters using an evolutionary
optimization method, which is called in this work as insilico evolution.
1.6. Thesis Organization
This thesis contains six chapters and is organized as described below.
Chapter 2 – Literature review of deterministic and stochastic cell cycle models is presented
Chapter 3 – Description of stochastic chemical kinetics followed by the application of the
stochastic formulation to develop basic cell cycle model of eukaryotic system is presented. Using
Monte Carlo strategy, the cell cycle model is used to obtain the solution to population balance
equations of cell growth.
Chapter 4 – The application of stochastic cell cycle model in predicting the treatment effect of a
chemotherapic drug on two types of cells, cancer and healthy is demonstrated. Also, a detailed
overview of mathematical modeling in assisting the chemotherapy, various approaches for
modeling and the associated challenges for developing accurate models are discussed.
Chapter 5 –Methodology to systematically select model parameters from the steady state
distributions of states of the cell cycle reaction network. Refinement of basic cell cycle model
presented in chapter 2 to make it more suitable for budding yeast is described and the insilico
evolution algorithm is applied to select more reasonable parameter values for the model.
Chapter 6 – Conclusions and future directions to extend the knowledge gained through this
modeling approach to more complex models is outlined.
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CHAPTER 2. LITERATURE REVIEW
There have been many studies dedicated to the modeling of eukaryotic cell cycle. These
studies started with simple models that do not depend on the molecular description of the cell
cycle. Later, when the discoveries are made about the molecular components and their
interactions controlling the cell cycle, more detailed studies are made. These mathematical
models of cell cycle are made to serve different goals. One of them is to understand the working
of the cell cycle and characteristics of different phases and transitions between those phases. For
this purpose, attempts are made to describe the cell cycle network in terms of differential
equations and using the dynamic systems theory to understand the qualitative features of cell
cycle such as limit cycle, hysteresis, bistability, cell size homeostasis, linking of growth to cell
cycle progression, creation of phenotypes based on mutations at the crucial transitions which are
controlled by checkpoints. A more sought after goal is to build comprehensive models that
combine individual studies of sub systems of cell cycle network to predict the behavior of
different phenotypes of cells under study. Comprehensive models of cell cycle of eukaryotes
exist that combine many features of eukaryotic cell cycles and many species and interactions.
Here, some of the mathematical models developed for each of the above goals are presented.
Both deterministic and stochastic models are presented in the literature, even though most of the
studies followed deterministic approach. First, deterministic models are discussed followed by
stochastic models. The general mathematical formulation of deterministic models involves
transforming the reaction network into differential equations and solving for average molecular
concentrations.
Mathematical modeling of cell cycle has a long history. It started with simple models of
cell cycle that does not contain many components in the network. Tyson (Tyson, 1991)
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developed a model for fertilized frog eggs cell cycle which is described by an autonomous
oscillatory behavior based on the levels of maturation promoting factor, a dimer of cdc2 and
cyclin, and it consists of alternation between S and M phases. Later, models were developed by
incorporating molecular interactions in the cell cycle. The focus was mainly on specific phases
or transitions between these phases. Obeyesekere et al. (Obeyesekere et al., 1995) described
control of G1 phase by a model including compounds cyclin E, cdk2 and retinoblastoma (Rb)
protein. Kohn (Kohn, 1998) proposed a model for mammalian cell cycle with an emphasis on the
transition at G1 – S interphase, studied the dynamics of the regulatory molecules influencing the
transition and provided an approach for synthesizing a realistic complex molecular reaction
network. They have followed a quasi-evolutionary approach in which functional capabilities of
the molecular components are evaluated by adding small subsets of reactions sequentially
towards increasing complexity to the reaction network, a method that can assist in the design and
interpretation of experiments. Qu et al. (Qu, 2003) followed a similar approach of dividing the
complex reaction network of molecules controlling the G1/S transition of a mammalian cell
cycle into small modules analyzed the effect of each module on the dynamics at the G1/S
interphase in terms of limit cycles, bistability using bifurcation analysis. Similar studies of G1/S
transition dynamics using bifurcation theory also exist in literature (Swat et al., 2004). A more
comprehensive cell cycle model for the S phase initiation (Barberis et al., 2007) relates the
critical cell size requirement to the G1/S transition by using a differential equation model that
stresses on the transport of components between nucleus and cytoplasm and the growth of cells
in G1 phase under various nutritional conditions.
A quantitative model for mitotic exit by down-regulation of cyclin dependent kinase
(cdk) by cdc14 in budding yeast is presented by Queralt et al. (Queralt et al., 2006). Their work
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mainly focused on verifying the molecular network controlling the mitotic exit by comparing
deterministic model predictions with experiments. Toth et al. (Toth et al., 2007) proposed
another cell cycle model of mitosis exit that explains the presence of two bistable switches in the
regulatory network controlling M-phase, using phase plane analysis.
Research group by Tyson and Novak have studied extensively eukaryotic cell cycles of
budding yeast and fission yeast, mammalian systems. Starting with models focusing on
molecular mechanisms for specific portions of the cell cycle, their studies extended to models of
more comprehensive nature. A ordinary differential equations (ODE) based model by Novak et
al. (Novak et al., 1999) explains the antagonism between cyclin dependent kinases and anaphase
promoting complex (APC) based on the mechanism of mitotic exit of budding yeast cell cycle
controls.
Tyson et al. (Tyson et al., 1996) developed a cell cycle model based on a network of
chemical reactions controlling the activities of M-phase and S-phase promoting factors to
understand the phenomena like limit cycle oscillations, stable steady states such as cell cycle
arrest. A deterministic model for morphogenesis checkpoint that controls the progression of cell
cycle during the bud formation in budding yeast is presented by Ciliberto et al. (Ciliberto et al.,
2003). The model is used to predict the behavior of cells in delaying the cell cycle progression
when external stimuli prevent the formation of bud. Bifurcation diagrams are used to analyze
how the checkpoint governs the progression of cell cycle.
Models are described that explain the dynamic behavior by concentrating on the entire
network of the cell cycle. Csikasz-Nagy et al. (Csikasz-Nagy et al., 2006) presented a generic
model of the eukaryotic cell cycle to explain the dynamic behavior of cell cycle concentrating on
entire network rather than on an individual phase. Their generic model can be used for describing
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the cell cycle behavior of various organisms that include budding yeast, fission yeast, frog eggs,
and mammalian cells. They have represented the cell cycle regulation in terms of biochemical
reactions of the interacting molecules and built detailed ODE models through proper selection of
rate parameters representative of organisms for which they are described. The dynamic analysis
of the cell cycle regulation is carried out using single parameter bifurcation diagrams to show the
linking of cell growth to cell cycle progression, creation of different phenotypes due to mutations
and achieving of cell homeostasis by these organisms.
Stelling and Gilles (Stelling and

Gilles, 2004) proposed a modular approach for

modeling complex cellular regulatory networks discussed with emphasis on model structure
selection, evaluating system dynamics and using experimental support to get realistic models. As
an example, control of mitosis in budding yeast is described using the modular approach in terms
of positive and negative feedback loops in the network.

Each module is represented by

differential equations and they used bifurcation theory to demonstrate the bistability and limit
cycle oscillations of the budding yeast cell cycle model.
A cell cycle model of budding yeast is presented by Lovrics et al. who have used time
scale analysis as a tool to test the cell cycle dynamics at the transition between steady states
(Lovrics et al., 2006). This is an alternative to using cell mass as a bifurcation parameter in
analyzing the dynamic behavior of cell cycle transitions between steady states that does not
depend on cell mass.
Logical methods are proposed to study the qualitative behavior of cell cycle models as an
alternative to differential equation based models that require molecular interactions in detail and
contain large number of parameters which need to be estimated accurately. These logical models
use regulatory graphs to represent the cell cycle network. Faure et al. use a Boolean network
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model based on network of a differential equation model of a mammalian cell cycle system that
is used to analyze cell cycle behaviors such as limit cycles, stable steady states (Faure et al.,
2006).
An important objective envisioned for cell cycle models is to use them to predict the
behavior of cells to carry out various biological functions, response to various environments. The
model should include all the crucial details of the cell cycle network to be realistic. Based on the
understanding of the earlier cell cycle models and detailed experimental observations on yeast
cell cycle, Tyson and Novak group came up with a most comprehensive model of eukaryotic cell
cycle. Their first comprehensive model of the budding yeast cell cycle (Chen et al., 2000),
developed by incorporating detailed biochemistry, genetic interactions of cell cycle control, was
able to predict the properties of wild type cells and 50 other phenotypes. This model had
adequate description of G1 to S transition; however, more details of the mitotic exit are included
in a later version of the model (Chen et al., 2004). This model was able to predict the phenotypes
of 120 mutant strains and can predict phenotypes of new mutants, helpful for finding out
biochemical rate constants of crucial cell cycle interactions which are difficult to measure
experimentally. Thornton et al. presented a mathematical model that models strains lacking APC.
The model was shown to accurately simulating APC- strains and 27 other phenotypes (Thornton
et al., 2004).
Ribeiro and Pinto have developed a model by combining signal pathways of proteins that
are crucial for tumor progression such as p53 pathway (important in causing apoptosis when
abnormalities like DNA damage and abnormal growth occur in the normal cell cycle
progression) and human cell cycle regulation pathway (Ribeiro and

Pinto, 2009). In the

deterministic approach, differential equations are formulated in terms of average concentrations
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of the cell cycle proteins and solving them using analytical or numerical techniques. However,
stochastic models differ from deterministic models.
Stochastic models are developed to capture the fluctuations that are common in cellular
processes. For gene networks, the concentrations of the reacting molecules will be very low, the
fluctuations are comparable to the number of molecules of that species in the system. The
chemical population changes as integral number of molecules and the reaction events occur as
discreet random events. If the regulatory protein stays in low molecular concentrations, then
fluctuations will influence the timing of the regulatory events in different cells leading to
different fates and thus leading to heterogeneities in populations. Another example of
stochasticity is at the “Checkpoint” pathways. Signal proteins control these regulatory events and
the fluctuations in their expression will cause uncertainty in the timing of those events and not in
the outcome. Thus, the duration of cell cycle for different cells varies and causes to the
heterogeneity in the population doubling times.
A stochastic model based on stochastic Petri net (SPN) approach is developed by Mura
and Csikasz-Nagy (Mura and Csikasz-Nagy, 2008) to include fluctuations to the number of
protein molecules in the network. The ODEs from a well-defined deterministic model are
converted to stochastic Petri net (SPN). The model predicts the behavior of wild type and many
mutant budding yeast cells. The stochastic model predicts some characteristics that could not be
observed by deterministic model on which it is built. It provides statistics of cell cycle duration
and average cell mass. However, one issue with the model is it gives to negative numbers due to
added noise to the number of molecules in less abundance. Their model considers does not
consider the randomness in the distribution of cell mass at division as it considers binary
division.
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For biochemical systems involving molecules in low numbers, Langevin-type equations
are used which give rise to stochastic differential equations in the model formulation as in
another work (Steuer, 2004). It is proposed that the system of differential equation, when
introduced noise, is not merely a small deviation from the deterministic behavior rather it will
have a different dynamic behavior. One issue with this type of models is that they are applicable
only when the molecules exist in large numbers.
Braunewell and Bornholdt investigated the stability of a cell cycle model of budding
yeast in the presence of intrinsic noise in the gene regulatory network (Braunewell and
Bornholdt, 2007). Their stochastic model uses a generalization of Boolean network dynamics
(Thomas, 1973).
Some stochastic models use stochastic formulation of chemical kinetics for the
biochemical reactions representing the cell cycle network. Stochastic approach to chemical
kinetics is described in the later chapters of this report. The evolution of the reacting system in
terms of the discreet reaction events is a discreet markov process (Gillespie, 1992) and is
described by the chemical master equation (Gillespie, 1992). The solution to the CME is
calculated using SSA presented by Gillespie (Gillespie, 1976). The stochastic chemical kinetics
approach is discussed in the next chapter of this report.
Arkin et al. (Arkin et al., 1998) emphasizes stochasticity in gene expression by studying
phase Lambda lysis – lysogeny decision circuit. Although, this model is not based on eukaryotic
cell cycle, the stochastic formulation of chemical kinetics used here is employed in other
stochastic models of eukaryotic cell cycles.
A software program is developed to simulate biochemical systems using stochastic
simulation approach which can be used for simulating cell division processes (Kierzek, 2002).
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They have tested the computational capabilities of the Gillespie‟s algorithm with their model
taking the examples of two cellular processes, one with large number of reactions and another
with small number of reactions. One limitation is the reaction set in any network, for this
program to be implemented, should be either first order or second order.
A stochastic model based on a probabilistic Boolean network on the protein interaction
network of the yeast cell cycle is presented in another work (Zhang et al., 2006). Stochasticity is
introduced by adding noise in terms of a temperature like parameter to the nodes representing
proteins or protein complexes in the Boolean network. They have found out that the biological
pathway, which is a cell cycle sequence of protein states, is stable for stochastic fluctuations and
for large noise, the network behaves randomly. Thus, they demonstrate that the network of
interacting proteins is robust under noise.
Sveiczer et al. present a stochastic model for fission yeast cell cycle based on a
deterministic model (Sveiczer et al., 2001). They have introduced stochasticity by incorporating
asymmetry of cell sizes at the time of division and assuming unequal volumes for nuclei of
newly divided cells. The model is able to predict the population distribution of wild type cells.
In another work, stochasticity is introduced into a deterministic model by adding
deviations to the deterministic rate of protein concentrations (Ullah and Wolkenhauer, 2009).
Thus, all the biochemical reactions rates and concentrations of proteins are described by
stochastic variables and the mathematical model is expressed in terms of stochastic differential
equations.
In the present work, a cell cycle model is developed based on the stochastic chemical
kinetics approach.
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CHAPTER 3. BASIC CELL CYCLE MODEL USING STOCHASTIC APPROACH
3.1. Stochastic Chemical Kinetics
In the stochastic approach, probability theory is applied to describe the kinetics of the
stochastic processes associated with the biochemical network. In the stochastic formulation, the
reaction propensity or the probability for that reaction to occur depends on the current states of
the system described by the number of molecules of each species in the network. The states of
the system evolve according to the discrete Markov process governed by a probability density
function which follows a chemical master equation (CME) (Gillespie, 1992).
CME is a deterministic differential equation in the probability of the system being in any
state of the system. Generally, reactions systems exist in many possible states and this leads to as
many differential equations in probability as there are possible states of the system.
The CME is given by

= state of the system, in terms of the number of molecules of „N‟ reacting species
= the probability that the system will be in state „x‟ at time „t‟ starting with an
initial state x0 at time t0.

= Probability that a µth reaction will occur in (t, t+dt), given that the system is in the state
„x‟ at time t
is the reaction propensity of µth reaction, which is stochastic equivalent of reaction rate
constant.

= Probability that a particular combination of reactant molecules of µth reaction

will occur in (t, t+dt).
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= number of distinct molecular combinations of the reactants of the µth reaction. For
example, for a first order reaction,
second order reaction it equals

simply equals the number of reactant molecules N, for a
, etc.

Clearly, the probability of reaction occurring depends on the state of the system given by
the number of molecules of the reacting species. A detailed derivation of CME is presented in
(Gillespie, 1992).
According to the CME, the state of the system at any time is a random vector that follows
the cumulative probability distribution evolving from the CME. However, analytical solutions of
the CME are possible only for simple cases. McQuarrie (1967) present examples of various
simple reacting systems for which analytical solutions are possible (McQuarrie, 1967). The
authors review the approach of Master equation for chemical kinetics. In most of the reaction
systems, numerical solutions are desired for the CME. One such method to exactly simulate the
stochastic behavior of the reaction system according to the CME is presented in the form of exact
stochastic simulation algorithm (SSA) by Gillespie (1976) (Gillespie, 1976). Through this
method, it is possible to deduce the time trajectories of reacting species resulting from discreet
molecular events. The algorithm is based on a joint probability function that determines the
reaction that occurs next and the time at which it occurs in a discreet stochastic process.
The joint probability function is given by,
Probability that, given the state x at time t, the next reaction will occur in the
infinitesimal time interval (t + τ, t + τ + d τ), and it will be µth reaction.
)
Where,

18

There are various numerical algorithms available that are exact or approximate to
simulate the time course trajectories of the reacting system. Gillespie (Gillespie, 1976, 1977)
presents two methods to simulate the SSA which are direct method and next reaction method.
3.1.1. Direct Method
In the combined probability density function, the probability of any reaction to occur
depends on the reaction propensity and on distinct combinations of the reactant molecules. The
higher the reaction propensity is the more likely it is that the reaction will happen next. The
algorithm for this method is presented in Table 1. It starts with the initialization of the state of
the system, i.e. number of molecules of each species, cell mass etc. Reaction propensities are
calculated for each reaction based on the current state of the system. Random numbers are
generated using reaction propensities to determine the next occurring reaction and the time of its
occurrence. State of the system is updated to reflect the occurrence of a selected reaction event.
The time interval between two successive state updates is called the interval of quiescence during
which the state of the system is assumed not changing. Since the time steps are relatively small,
any changes in the state like cell mass will not affect the propensities much in the interval of
quiescence. This procedure of selecting random time and reaction followed by state update
continues till the end of the simulation and the time course trajectory of the state of the system is
obtained.
3.1.2 First Reaction Method
This is exactly same as the direct method, but the implementation to obtain the solution of SSA
is different. For each of the reactions, time of occurrence is calculated as if no other occurred
first. The difference between the two methods is that more random numbers are used with the
first reaction method. The algorithm for the first reaction method is presented in Table 2.
19

Table 1: Direct Method - Algorithm
Step 0:
Initialize the state
Input the values of the propensities,
Initialize the time t = t0
Step 1:
Calculate
Calculate
Step 2: Generate uniformly distributed random numbers in [0,1], r1 and r2
Select
Select µ as an integer satisfying ,
Step 3:
Advance t = t + τ
Update the state of the system according to the execution of reaction µ.
Repeat step 1 to step 3 until final time.

Table 2: First Reaction Method - Algorithm
Step 0:
Initialize the state
Input the values of the propensities,
Initialize the time t = t0
Step 1:
Calculate the reaction propensities,
Step 2:
Select M random numbers r1,…rM from the uniform distribution [0,1]

Select such that
Select µ as the index

for which

is minimum.

Step 3:
Advance t = t + τ
Update the state of the system according to the execution of reaction µ.
Repeat step 1 to step 3 until final time.
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These exact stochastic simulation algorithms will be efficient when used for reaction
systems with small set of reactions and reacting species. The biochemical reaction networks used
to represent the intracellular processes contain large number of reactions and components. For
such cases, exact simulation algorithms become computationally expensive. There are
approximate algorithms available that improve the computational speeds.
Gibson and Bruck (2000) present next reaction method that is developed based on first
reaction method to reduce the use of random numbers and to reduce the computational load by
introducing the concept of priority index queue (Gibson and

Bruck, 2000). Number of

calculations of the reaction propensities is reduced drastically with the use of cleaver data storage
structures, by modifying and reusing the values of propensities in the priority queue.
An optimized direct method is used by Cao et al. (2004) (Cao et al., 2004) which is an
optimized version of the direct method proposed by Gillespie (1977) (Gillespie, 1977). The
search depth for identifying the next reaction that occurs in the algorithm is reduced by arranging
the reactions in decreasing order of the number of times each reaction fires in a time span of
interest.
Gillespie (Gillespie, 2001) presented an explicit tau-leaping method according to which
number of times each of the reaction fires is decided by a poisson random variable, in a leap or
subinterval of time that does not result in much changes to the reaction propensities. The method
is explicit in the sense that the propensities for the next time step are evaluated based on the
current state. This method is advantageous when there are moderately large numbers of reacting
species. As each reaction event may result in the change of only one or two molecules, a large
number of firings of the reactions will avoid the many steps required by the execution of SSA.

21

The selection criterion that does not result in much change in the propensities is improved in
another approach (Gillespie and Petzold, 2003).
Binomial leap methods for stochastic chemical kinetics use binomial random variable
instead of Poisson random variable for determining the number of firings of each reaction in a
time leap (Tian and Burrage, 2004). This way, possible reaction firings can be restricted and
negative molecular numbers are avoided when large time steps are used.
By characterizing some of the reactions as critical reactions for which the reacting
species are in the danger of exhaustion, a modified tau-leap method is used to avoid negative
molecular numbers during the simulation (Cao et al., 2005b). It is proposed as an improvement
over the binomial leap methods.
To avoid the instability for stiff reaction systems at larger time steps of the explicit tauleaping method, an implicit tau-leaping method is proposed that has greater numerical stability
(Rathinam et al., 2003). In the implicit version, the propensities are evaluated based on the
estimated future state of the system that ensures stability. Limitation of these tau-leap methods is
that they require the values of propensity functions to be approximately constant. This
requirement is realizable only when the species population is large compared to 1.
In the context of the limitations of tau-leap methods in applying to systems with low copy
number of molecules, hybrid methods have been proposed. Hybrid methods combine the
deterministic regimes expressed by chemical Langevin equation with the discreet stochastic
regime expressed by SSA. Hybrid methods account for multiscale nature of reacting systems.
Multiscale phenomena occur at time scales and population scale. On time scale, some reactions
occur very fast and always will be in equilibrium state while slow reactions dominate the
reaction dynamics. On population scale, some of the species exist in small number which is to be
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dealt using discreet approach whereas some species exist in large numbers that can be accurately
represented by deterministic approach.
A simplification to the stochastic kinetic model is made by applying quasi steady state
approximation (QSSA) to the SSA (Rao and Arkin, 2003). QSSA assumes the rates of change of
intermediate species to be zero for time scales of interest. Using QSSA, they have reduced the
complexity of the model by reducing the number of reactions and molecular species that have
fast dynamics and are not of much interest.
Cao et al. (Cao et al., 2005a) describe a partial equilibrium assumption that executes the
SSA for slow reactions with the propensity functions calculated based on the partial equilibrium
values of the fast species molecular concentrations. This method avoids the expensive simulation
of the fast reactions.
All these exact or approximate algorithms greatly help to simulate the stochastic behavior
of many biochemical systems of interest.
3.1.3. Monte Carlo Strategy
Using any of the above algorithms, it is possible to traverse along the evolving state of
the system by following similar procedure. The procedure simulates a sequence of state
dependent random variables which is equivalent to the evolution of the state of the biochemical
reaction system of the cell cycle. Starting with an initial state, time for the next reaction and the
index of the next reaction is generated in terms of the state of the system and these two random
variables determine the next updated state of the system. This procedure is continued till a
desired final value of time.
Under identical initial conditions, different independent stochastic simulations will give
different realizations of the state. This principle is used in Monte Carlo strategies to obtain the
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distributions of states. The strategy is to repeat stochastic simulation up to a final time, large
number of times and the desired properties obtained in each trial are summarized to deduce the
distribution of properties.
3.2. Stochastic Cell Cycle Model
3.2.1. Solution to Population Balance Models Using Cell Cycle Model
One interest in obtaining the population distributions of cell populations is in the
chemotherapic drug applications where researchers want to study the response of cell
populations to various drug actions. Due to the heterogeneity among the cell population, each
cell responds differently to a given action of chemotherapic drug and thus a mathematical model
to describe the population behavior of cells will be useful to estimate the curing potential of a
drug. Population balance models are used to deduce the population distribution of properties of
various particulate systems.
Population balance models (PBM) are number balances on population of particles which
include biological cells. Population balance models for describing biological cell populations are
different from those used for other particulate systems such as crystallizers, bubbles or aerosols.
Dependent variable of a population balance is the distribution of states (Eakman, 1966;
Fredrickson, 1967; Ramkrishna, 2000; Hjortso, 2006). For a population of cells that follow a cell
cycle model of biochemical network of cell cycle proteins, the distribution of states is a
probability distribution indicating the frequency of cells with a given cell mass and a given
number of molecules of the molecular components of the cell cycle network which may involve
hundreds or even thousands of metabolites and similarly large complex biochemical reactions.
This leads to a large number of state variables in the population balance equations the solutions
of which are difficult to obtain due to the high dimensionality. Solution methods such as moment
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methods and methods of weighted residuals will work well only for low dimensional problems.
Monte Carlo simulations are suggested as an alternative method to obtain the solution of
population balance problems of high dimensionality (Shah et al., 1976; Shah et al., 1977;
Ramkrishna, 2000). Previously, Sherpa and Hjortso (unpublished work) described how the
distribution of cell states can be obtained from the Monte Carlo simulations of a cell cycle model
using stochastic chemical kinetics approach. The implementation and solution of this cell cycle
model is presented here.
3.2.2. Description of the Basic Cell Cycle Model
A simple model adapted from the deterministic model of Tyson and Novak (Tyson, 2000)
and not specific to any organism is used as the biochemical network representing the interactions
among the proteins involved in cell cycle regulatory system.
The cell cycle network is shown in Fig. 1 and it is not specific to any particular organism.
Several cyclin-kinase complexes that normally take part in the chosen model are lumped into a
pseudo compound, cyclin/Cdk as shown in Fig. 1. Activated cyclin/Cdk activates conversion of
APC to its inactive form while active APC activates degradation of cyclin, thereby removing the
activated cyclin/Cdk complex. Increased accumulation of cyclin/Cdk initiates production of an
activator protein which activates conversion of APC from the inactive form to the active form.
The cell cycle model contains two checkpoints or irreversible transition points. The first
checkpoint is called the “start event” and is triggered when the number of molecules of
cyclin/Cdk exceeds a specified threshold value. This event occurs when the cell switches to a
state with a high amount of cyclin/Cdk and corresponds roughly to the transition from the G1 –
phase to the S – phase. The second checkpoint is passed only if the cell has passed the start event
and when the number of molecules of cyclin/Cdk drops below a specified value. This point
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corresponds roughly to the state after DNA replication has finished and the chromosomes are
aligned on the mitotic spindle. In this model it signifies cell division.

Figure 1: Schematic of the eukaryotic cell cycle network. (Sherpa and Hjortsø – unpublished)
Individual reactions and expressions for propensities are shown in Table 3. The binding
between cyclin and Cdk is assumed fast such that rate of cyclin/cdk formation is equal to the rate
of cyclin synthesis. Degradation of cyclin/Cdk is modeled as two parallel reactions, one which is
constitutive another which is activated by active APC. The model does not include reactions for
synthesis and turnover of Cdk and APC as both are assumed to be maintained at constant
concentrations in the cell through the cell cycle.
3.2.3. Implementation and Solution of the Cell Cycle Model
The model contains 4 discreet variables, number of molecules per volume of cyclin/Cdk
(X), of active and inactive APC (Ya, Yi) and of activator protein (A) and one deterministic and
continuous variable, the cell mass (m). Formation of cyclin/Cdk is assumed to be rapid compared
to the other reactions and free cyclin is therefore not considered in the model.

26

Table 3: The reactions of the eukaryotic cell cycle model
„m‟ is the cell mass, X – number of molecules per volume of cyclin/Cdk; Ya – of active APC; Yi –
of inactive APC; A – activator protein
Reaction Stoichiometry
Reaction propensity, cn Reactant combinations,
Number
hn
1
2
3
4
5
6
7

It is assumed that all the cells divide continuously without considering dormant cells,
differentiated cells and mature cells. Cell mass is the only continuous state variable and it is
assumed to be growing according to first order growth kinetics and it is independent of the
values of the discreet state variables. Cell mass increases exponentially with time as

Where,

is the initial cell mass at time

– specific growth rate.

;

Due to the stochastic nature of the cell cycle oscillator in this model, there is always a
possibility that the trajectory of the system can escape from the oscillatory state. In that case, cell
never passes the second checkpoint and therefore never divides. Consequently, cell mass
increases without bounds and a cell is assumed dead when its mass exceeds a specified value. In
one way, it represents the natural death that occurs in cells due to errors in the regulatory system.
Hence, cell deaths due to any drug action on the cell population will be in addition to the natural
deaths occurring in the normal cell cycle.
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Asymmetric division of mother cells is considered using a unimodal probability
distribution function as one source of cell cycle variability. Cell mass is assumed to partition
according to the function

at the time of cell division, where

is the

probability that a dividing cell of mass M will give rise to a new cell with mass between m and
m+dm.

The function is a bell shaped curve situated between a minimum possible cell mass
and

,the maximum possible cell mass that can result from division of a cell with

mass M. Perfect binary fission is a special case of this distribution. The concentrations of all
other model variables are assumed preserved in a division, i.e. the number of molecules of each
of the discrete variables does not change.
3.2.4. Monte Carlo Solution for Population Distributions
The reactions among the four discreet variables are modeled using stochastic chemical
kinetics. Gillespie‟s algorithm for direct method described in the previous chapter is used to
simulate the time course trajectory of state of the system in the cell cycle. Monte Carlo strategy
is used to obtain the population distribution. Because of the stochastic nature of the model,
different simulations of the cell cycle model with same initial state will have different outcomes
and the distribution of the cell states follows the probability distribution given by the CME for
the assumed cell cycle biochemical network.
All the parameters and state variables are given arbitrary units as the model does not
represent any organism. In the absence of parameters representing any particular organism,
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model parameters are systematically tuned to obtain reasonable oscillatory dynamics
qualitatively resembling eukaryotic cell cycle.
The stochastic model for simulating the cell cycle progression of a single cell is modified
to include multiple cells at the start of the simulations. The total number of molecules of each
species involved in the cell cycle is specified for all the cells as random initial states of the cell
population. By using these random initial states for different cells, another source of extrinsic
heterogeneity of cell population is included in addition to the asymmetric division of cell mass.
As time increases, cells continuously undergo division or death thereby changing the size of the
population. Thus, these simulations once started can be viewed as cell population that is
changing over time. From these simulations, it is possible to obtain the time trajectories of total
number of live cells present and the total number of cell deaths occurred in the cell population.
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CHAPTER 4. APPLICATION OF STOCHASTIC CELL CYCLE MODEL IN
CHEMOTHERAPY
4.1. Introduction
Chemotherapy is the usual treatment strategy in the earlier stages of tumor development
or after the surgery. Conventional chemotherapy involves strategic administration of drug that
kills tumor with less toxicity to normal cell tissues (Sanga et al., 2006). Chemotherapic drugs are
mainly classified as cell cycle non-specific, cell cycle specific drugs. Cell cycle specific drugs
facilitate the design of treatment strategies that exploit the difference in the cell cycle kinetics of
cancer cells and healthy cells to selectively kill cancer cells. Thus, there has been growing
interest in the development of more cell cycle specific drugs in treating tumors.
There are many challenges and goals that need to be addressed for making the field of
chemotherapy successful. Among these challenges, toxicity to the normal cells receiving the
same treatment is a primary concern. Since healthy cells and cancer cells both live in the same
microenvironment utilizing the nutrients, application of chemotherapy targeting cancer cells will
also affect healthy cells which leads to varieties of toxicities. Thus the primary challenge of
chemotherapy is to kill cancer cells with minimal toxic effects to normal tissues. Both
biochemical and kinetic resistance to the drugs affect treatment outcome (Norton and Simon,
1986) which should be handled carefully. Biochemical resistance is the resistance developed by
the tumor cells to the acting chemotherapic drug. Kinetic resistance is observed for phase
specific drugs which are only effective in particular phases of the cell cycle and are ineffective in
the other phases. Multiple drug resistance is another problem of chemotherapy where a single
mutated gene results in resistance to many drugs of different biological composition and
configurations and understanding its evolution and control is another important challenge
(Swierniak et al., 2009). Delivered drug needs to overcome various resistances and barriers
30

before it reaches its target sites on tumors and a successful delivery of the drug to its target
requires detailed understanding of the effect of these barriers which is separately studied as drug
pharmacokinetics. Individuals have different drug pharmacokinetic properties and variations in
the immune systems which result in differences in birth and death rates of cells, evolution of
drug resistance. Due to this highly heterogeneous nature of the tumors among individuals, same
type of drug and its administration strategy may not work well for all the individuals in a similar
manner and hence chemotherapic strategies should be tailored to each patient. Even for a given
patient, due to the inherent heterogeneities among the tumor cells, not all the cells respond
uniquely to given drug and thus it is important to identify the best treatment strategy that is
characterized by the dose, exposure time, periodic or continuous administration of the drug
without inducing more toxicity to the patient. Using multiple drugs is usual practice due to
toxicity considerations and due to evolving resistance to a single drug, many novel, minimally
cross-resistant drugs have been identified. Identifying the best combination of these drugs and
their administration regimens is crucial for achieving best results from the treatment which is
difficult to accomplish by experience from clinical practice alone. During the drug development
stage, probability of cure of a newly developed drug should be known before deciding on its
introduction into the market. Millions of dollars are spent by pharmaceutical companies on costly
clinical trials and lab experiments to screen potential drug candidates with high probability to
achieve cure. However, the drug development process is considered to be highly inefficient due
to the high failure rate (>75%) of most of the drug candidates (Sanga et al., 2006).
Mathematical modeling and bio computation in combination with experiments and
clinical trials is considered to be a valuable tool by the cancer research community to address the
challenges hampering the success of chemotherapy. Mathematical models are useful for
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generating predictions about the optimum treatment strategies to achieve treatment objectives
which can be tested through accurately designed experimental and clinical studies (Goldie and
Coldman, 1986). Thus, Time, money, energy, animals can be spent on conducting more
statistically significant clinical trials and experiments.
In this chapter, application of the stochastic cell cycle model, described in the previous
chapter, in evaluating the effect of scheduling and doses of cell cycle phase specific drugs on
tumor cells and healthy cells is presented. The stochastic model described in the previous chapter
for obtaining the distributions for cell population based on the dynamics at single cell level is
used as tumor growth model. The chemotherapic model based on the stochastic cell cycle model
formulation in its preliminary stage is aimed at a long term goal of addressing the previously
mentioned challenges hampering the progress of chemotherapy field.
In the next section, general features of chemotherapic models and a review of previous
models in literature is presented along with an outline of the present model development. It is
followed by a section on the development of chemotherapic model based on cell cycle model is
described and the simulation methodology for evaluating various chemotherapic strategies is
delineated. Results from drug testing simulations are presented and discussed followed by
conclusions.
4.2. Literature Review on Mathematical Models in Chemotherapy
Mathematical approach for chemotherapy has a long history. Even though theories were
formed long ago, due to the lack of sufficient computational power and experimental and clinical
data for tumor growth, research in this field gained momentum only since late 90s. With the
advent of super computing power and of high end experimental techniques to trace the tumors
from biopsies at gene level, extensive research is devoted for developing simulators that can
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predict response to multiple drugs, tailor treatments to individuals by integrating details at
multiple scales (Gardner and Fernandes, 2003). A pictorial representation of multiple scales at
which chemotherapy modules are developed is presented in other studies (Sanga et al., 2006;
Ribeiro and Pinto, 2009). Models exist in literature, developed for individual modules and also
those developed for integrating different modules. References to different mathematical models
involved in the description of tumor growth for cancer chemotherapy are found in (Swan, 1990;
Gardner and Fernandes, 2003; Sanga et al., 2006; Venkatasubramanian et al., 2008; Swierniak
et al., 2009). These models are classified in many ways –deterministic and stochastic; spatially
homogeneous and heterogeneous; cell cycle specific and non-specific. Most of the mathematical
models follow deterministic approach where behavior of cancer cells is averaged rather than
considering individual variations among the cells which cannot be neglected when describing the
cancer phenomena. Stochastic models are developed to address the randomness prevailing in the
origin and progression of cancer. Spatially heterogeneous models focus on the detailed
vasculature in the tumors and on the distribution of nutrients, drugs in the highly irregular
structures inside the tumor. A detailed review of modeling approach for spatial variations is
given in (Sanga et al., 2006). Cell cycle specific models are specifically designed to facilitate the
testing of cell cycle specific drugs.
Mathematical models in chemotherapy differ in the way they include the details to
represent the tumor systems and the effect of chemotherapy viz. growth pattern of tumors, drug
pharmacokinetics, drug resistance, toxicity, type of killing effect of the drug on tumor cells, cell
cycle specificity, combined action of multiple drugs and also they differ in the goals they are
designed to achieve. These categories are combined into two main features of the chemotherapic
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models, one is to describe the growth of tumor and the other is to incorporate the effect of drug
that kills some or all of these cancer cells.
4.2.1. Describing the Growth of Tumor
Models representing tumor growth can be broadly classified into two categories:
homogeneous models that consider tumor as homogeneous population of cells and models that
consider spatial heterogeneity of tumors (Venkatasubramanian et al., 2008).
In the literature, many models are found that use homogeneous assumptions. There are
simple exponential, Gompertzian and logistic growth models that does not relate to the biological
details of the tumor system (Norton and Simon, 1986; Martin et al., 1992; Iliadis and Barbolosi,
2000), (Gardner, 2002). Tumors contain relatively less number of cancer cells immediately after
the surgery or in early stages of cancer and the tumor growth is approximately exponential. As
the tumor grows larger in size as in late stage of the cancer, transport limitations of blood supply
cause the cell population to reach a plateau after certain size which is generally modeled using
Gompertz and logistic equations. Multiple compartmental models differentiate various phases of
the cell cycle into homogeneous compartments to obtain cell population dynamics. Different
phases of the cell cycle viz. G0, G1, S, G2, M and their sub phases and a separately added death
phase are denoted by these compartments for cell cycle specific models. Cell cycle non-specific
models generally use proliferating and quiescent compartments. The progression of the cell
through the compartments is described by parameters such as transition rates between the
compartments, cell birth rates and decay rates, cell kill rates due to drugs. Depending on whether
these are parameters are fixed or variable, compartments may be deterministic or probabilistic.
Some studies use both deterministic and probabilistic compartments in their models (Dibrov et
al., 1985). The number of compartments considered depended on types of drugs considered in
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the chemotherapy. For example, models that consider only cytotoxic drug propose two
compartment models, whereas those including the additional cytostatic drug or recruiting agent
propose three compartmental models (Ledzewicz and Schattler, 2002).
Another approach is to use cell population balance models (PBM) which can be
structured or unstructured for describing tumor growth. For unstructured population balance
models, cells will undergo transitions at different phases or stages at prespecified rates.
Unstructured population balance models result in ODEs which may not represent the cell cycle
phase delays (Gaffney, 2004). Structured models of cell population dynamics account for the
variability among the cells in age, mass, RNA content, volume and other physically measurable
properties (Webb, 1990). The transition rates between the phases depend on the structured
variable and these models generally result in partial differential equations or integro-partial
differential equations in the structured variables. Webb (1990) developed a cell cycle specific
model with age and size structured population balance model. Brikci et al. (2008) (Brikci et al.,
2008) used age and cyclin structured PBM to simulate the growth of cancer and normal cells in
parallel using two compartments – proliferating and quiescent. Some growth models are
developed based on theory of branching processes (Goldie and Coldman, 1983; Day, 1986).
Due to the transport limitations of oxygen and nutrients, tumors form a heterogeneous
mass that have wide variations in space. Modeling these factors interacting in spatial domain is
considered in some studies as a more realistic approach than homogeneous assumption of the
tumor mass (Sanga et al., 2006; Swierniak et al., 2009). These models consider transport effects
of drugs, nutrients in the micro environment surrounding cells. The microenvironment
surrounding these cells comprises of mass of other cancer cells, a network of blood vessels that
supplies nutrients, oxygen and drug compounds to the cancer cells which is referred to as
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vasculature. Some studies do not incorporate tumor vasculature in their models which are
referred to as avascular tumor growth models (Venkatasubramanian et al. 2008 and the
references therein) and other studies include vasculature in their models (Sanga et al., 2006).
More complex models describe tumor growth by incorporating angiogenesis, process by which
new blood vessels are formed from the existing vasculature (Sanga et al. 2006 and the references
therein). Generally these tumor models are described mathematically in terms of partial
differential, ordinary differential, and algebraic equations and solved using numerical
simulations. Stamatakos et al. developed a 3D model for tumor growth based on the 3D structure
of the tumor and functional gene data.
Another approach to describe the growth of the cells is using mechanistic models that
describe the growth of individual tumors in relation to biochemical network of various proteins
and genes that are involved in cell cycle regulatory network errors of which are linked to the
origin and progression of cancer (Chappell et al., 2008; Ribeiro and Pinto, 2009).
4.2.2. Describing the Effect of Drug on Cancer Cells
When it comes to the cell kill due to drug, there are many ways it is implemented.
Response of cancer cells in monolayer cultures (in vitro) is different to that in vivo. The
interaction of drug with blood and bodily environment into which it is injected plays a crucial
role in the final response of cancer cells to drug. Effect of micro and macro environment
surrounding cells on drug is studied as drug pharmacokinetics and the effect of drug on cancer
cells is referred to as drug pharmacodynamics.
Pharmacodynamics (PD)
When PD is modeled, an additional cell kill term is added to the tumor growth model.
This cell kill term may follow the traditional log-kill concept which uses first order dynamics, a
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Norton-Simon type model, or a bilinear law that multiplies both the drug concentration and cell
concentration. According to log-kill concept, a given dose kills a constant proportion of a tumor
cell population irrespective of the size of the tumor (Ledzewicz and Schattler, 2002). NortonSimon‟s hypothesis (Norton and Simon, 1986) says that rate of cell kill is also proportional to
the growth rate of the unperturbed tumor according to which proportion of tumor cells killed by a
given dose of drug decreases with increase in size of the tumor. Cell kill terms of bilinear
expression (Ledzewicz and Schattler, 2007; Ribeiro and Pinto, 2009) are considered mainly
when drug pharmacokinetics cause changes in drug concentration with time. Effect of cell kill is
included in these terms in the form of cell kill rates. The relationship between the cell kill effect
and the drug dose are given by dose response curves. The dose is obtained from the “Area under
the concentration versus time of exposure of the drug (AUC)” curve to measure the cell kill
effect of the drug. AUC gives the cumulative dose of the drug during the total drug exposure
time. Other than dose response curves, empirical models are also used to relate the cell kill effect
to the drug dose. A simplified relationship considers cell kill effect to be “on- off” type, that
results in killing of all the cells during the drug effective period (Webb 1990, Augur 1988). Hill
model and Exponential kill models (Goldie and Coldman, 1983; Gardner, 2000) are often used
for this purpose. In Ledzewicz & Schattler (2005), PD is given by Emax, Sigmoidal relations.
More realistic functions which describe the saturation effects include Michaelis–Menten formula
which is more suitable for fast acting drugs that saturate at high concentrations or the sigmoid
function that more accurately approximates the effectiveness at both lower and higher
concentrations of the drug (Swierniak et al., 2009). According to above relations, response to the
chemotherapic drug by using the value of dose obtained from AUC will be same for any amount
of drug exposure time. However, it is mentioned that factors like cell cycle specificity of the
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drug, cell cycle time, duration and concentration of the drug exposure at the site of action, level
of drug resistance affect the shape of the dose-response curves (Gardner, 2000). By incorporating
such factors, Laveuser et al. (1998) (Levasseur et al., 1998) proposed Modified Hill model and
Gardner (2002) (Gardner, 2002) used a modified exponential kill model both resulting in
sigmoidal dose response curves. Some researchers speculate that dose of the drug may not be the
proper measure to introduce the effect of cell kill and they propose peak DNA bound drug
concentration to replace the total dose of the drug (Sanga et al., 2006).
Pharmacokinetics (PK)
Intensity of the effect of the drug is influenced by the ease with which it can be delivered
to the target. Drug pharmacokinetics plays a crucial role in this. Drug has to overcome many
barriers before it is delivered to the target location. The cumulative effect of these barriers is
described by compartmental modeling (Godfrey, 1983; Jacquez, 1996) in which different
components are interconnected in the overall process of drug delivery to the target from the drug
intake into the extra cellular environment. Various components that are generally represented by
the compartments in pharmacokinetic models include lesion interstitium, cell membranes,
intracellular organelles, blood-brain barrier and other barriers obstructing successful drug
delivery to the target. One of these compartments gives the concentration at the tumor site and it
appears as the drug concentration in PD equations.
Different multi-compartmental models are proposed that are either linear or non-linear
PK models. Simple linear models are proposed in the form of first order linear differential
equations. An accurate representation is done by introducing nonlinearities into the models.
Simple nonlinearities are introduced in the form of bilinear systems (Ledzewicz and Schattler,
2005,
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Venkatasubramanian et al. (2008) use both linear and non-linear pharmacokinetics in a three
compartmental model: Central compartment represents blood plasma and two peripheral
compartments represent organs and tissues that have poor distribution of drug. Ribeiro (2009)
use a three compartment model that represents blood, extracellular environment and tumor cell
as the compartments.
Drug Resistance
Drug resistance is another phenomenon by which cancer cells evade the action of drug
and it is an important challenge to be overcome before making chemotherapy successful.
Mutations to crucial genes involved in the cell cycle regulatory pathways such as DNA repair,
apoptosis and to those involved in the drug related activities like absorption, distribution,
metabolism, excretion are considered to be main reason for the evolution of drug resistance. The
drug resistance is described by a single, random irreversible mutation (or point mutation)
(Coldman and Murray, 2000) to a crucial gene or by reversible multistep mechanism of gene
amplification through which multiple copies of the mutated gene are acquired in leading to
different levels of drug resistance. A general approach in point mutation models is to divide the
cell population into different clones each having a different type of mutated single gene along
with the non-mutated drug sensitive cells. During the cell growth, cells from one clonal category
to another transform through single random mutation event characterized by mutational
probability rates. Drug resistance models built based on the mutational probability rates obtained
from patient biopsies (Gardner, 2002) will help to describe this phenomenon accurately. For
describing gene amplification, a similar approach is followed where cells are categorized
according to the number of mutated gene copies and reversible transformation of cells from one
category to its adjacent category with probabilities of gene amplification and de-amplification.
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4.2.3. Previous Models of Chemotherapy
An extensive literature review of studies for chemotherapic models is presented in the
Appendix E. Some of the studies relevant to the present work are mentioned here. Mathematical
models that describe the controlling and regulatory mechanisms at the single cell level will help
to explain the patient specific treatment effect of drugs. In response to treatment, cells may
undergo apoptosis or develop defense mechanisms such as drug resistance or differentiation. If a
mathematical model is developed based on these regulatory processes at the single cell level to
obtain the population characteristics, if it is tractable computationally or mathematically, will
greatly aid in the patient tailored treatment. Ribeiro & Pinto (2009) has developed a deterministic
biochemical network based multi-compartmental model that depends on the molecular
mechanisms of cancer development, neglecting drug resistance, cell cycle specificity and toxicity
to normal cells. The deterministic approach follows as forming the differential equations for
various proteins involved and solving them analytically or numerically assuming average
concentrations. They combined signal pathways of proteins that are crucial for tumor progression
such as p53 pathway (important in causing apoptosis when abnormalities like DNA damage and
abnormal growth occur in the normal cell cycle progression), targeted by drug action, and cell
cycle regulation pathway. They have combined this network module with a compartmental
PK/PD model following a multi-scale integrative approach. Another network based deterministic
model is presented by Chappel et al. (2008) (Chappell et al., 2008) a single drug kinetics is
linked directly to the cell cycle reaction network and thus avoiding the necessity for using
separate PD model. Without considering drug resistance, toxicity they have combined this
complete network dynamics with PK following an integrated approach for evaluating the effect
of varying doses on cancer cells.
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4.2.4. Present Model
The stochastic cell cycle model is combined with PD and PK laws to form an integrated
chemotherapic model. The model is formulated to test the effect of multiple cell cycle phase
specific drugs. The model formulation facilitates the evaluation of multiple toxicities in response
to treatment along with tumor response to chemotherapic drugs. As more information becomes
available about specific genes involved in oncogenesis and drug responses and as methods to
measure cell kinetics become feasible to perform in a clinical setting, it appears that a network
based model can be used to account for individual patient specific models. In contrast to the
network based models mentioned earlier (Chappell et al., 2008; Ribeiro and Pinto, 2009) which
are deterministic, a stochastic approach is to account for variable cell cycle kinetics of cancer
cells. The intrinsic and extrinsic heterogeneities that are commonly observed in cancer cell
population can be handled suitably using stochastic approach. The development of the overall
chemotherapic model is described in the next section.
4.3. Using the Stochastic Model for Drug Screening and Efficacy Tests
It was discussed earlier about obtaining the growth of cell population based on Monte
Carlo simulation of the stochastic cell cycle model. Here, the same model is used to obtain the
growth of tumor cells and healthy cells. Repeating simulations with different initial number of
tumor cells and their random initial states, it is possible to simulate the intra and inter
heterogeneities in tumor growth among patients. By combining these simulations with cell kill
due to drugs and with a proper measure of cure of cancer, the probability of cure obtained will
represent results from actual clinical trials. Description of various modules of the chemotherapic
model is presented below.
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4.3.1. Incorporating the Effect of Drug into the Model (Pharmacodynamics, PD)
Drug dosage is an important parameter in optimizing the drug treatment strategies for any
disease. In a conventional sense, drug dosage denotes concentration or amount of the drug that is
administered into the body. Generally, cell cycle phase specific chemotherapic drugs act by
obstructing the natural progression of cancer cells through their cell cycle. Since the proposed
reactions in the model are crucial for multiplication of cells through the processes of replication
and division in cell cycle, inhibition of some of the reactions affects the growth of the cell
population either by killing the cells or by delaying their progression through cell cycle. Thus, it
is proposed here that a chemotherapic drug acts on the cells by inhibiting any of the biochemical
reactions that are part of the cell cycle regulatory network. Inhibition of any reaction is carried
out by reducing the values of the corresponding rate parameters by multiplying with a factor
which named as inhibition factor. Extent of inhibition of targeted reaction varies with the
concentration or amount of drug present in the body. Thus, in the present model, effect of a drug
is incorporated by the degree of inhibition of the reaction that the drug targets. This is different
from the generally followed PD relations to incorporate the effect of drug on the cancer cells, for
example dose-response curves that relate dose to the killing effect of drug on the cells. Since, the
model is in its primitive stages and there is not enough complexity in the model, any exact
correlations between drug dosage and degree of inhibition are not introduced. So, comparison of
two types of treatments for different drug dosages is done by comparing different degrees of
inhibition of the target reaction. Furthermore, the term „dosage‟ is used frequently in place of
„inhibition factor‟ in the later discussions.
4.3.2. Types of Drug Administration (Drug Pharmacokinetics, PK)
Continuous and periodic types of drug administration are considered in the present study.
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In the continuous administration, the degree of inhibition of a reaction is constant while the drug
is being administered and falls to zero when the drug is no longer administered. This would be a
simple model of e.g. a drug that is administered by a continuous drip or by a time formulation
and removed quickly from the body once administration of the drug ceases. For simulations
involving continuous administration, rate constant of the target reactions of the drug is multiplied
by corresponding inhibition factors and their values kept constant from the time of drug
administration till the end of the simulation.
A more complex scenario involves periodic administration of a drug which is modeled as
periodic changes in the degree of inhibition of the target reaction, combined with removal of the
drug from the body following administration. After the drug administration, it can be removed
from the body by being metabolized or by excretion (or by both). This type of time varying drug
concentration is incorporated by different pharmacokinetic models that mainly use single or
multiple compartment models as described in earlier sections. Here, a simple model is adopted
where the first of the two mechanisms mentioned earlier will be modeled as a first order reaction,
the latter as a zero order reaction. Doing so suggests that the degree of inhibition versus time can
be modeled as an exponential decay or a linear decay. Hence, three cases of periodic
administration are considered, viz. constant degree of inhibition (no decay of the drug during
injection period), exponential decay and linear decay of the degree of inhibition of the drug. Fig.
2 shows periodic administration characterized by the starting time of the drug injection, time gap
between the two successive drug injections, effective time of the drug during which only drug
shows its inhibitory effect and finally the degree of inhibition. During the exponential and linear
decay cases, the inhibitory effect of the drug is assumed to fall to 10% of the value that is at the
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start of the injection and upon which action of the drug is neglected till the start of the next
periodic injection.

Figure 2: Schematic of the periodic drug administration.
4.3.3. Classification into Target Cells and Normal Cells
Cell population is classified into normal cells and target cells by selecting two separate
sets of kinetic and growth parameters of the stochastic cell cycle model as shown in Tables 5 &
6. Based on the type of cancer, cancer cells may divide at a faster or slower rate than the normal
cells do. In the simulations of the present model, abnormal cells are assumed to be having higher
growth rate than the normal cells which can be noticed from the values of the specific growth
rate in the Tables 5 & 6. Monte Carlo simulation of the model for each set of parameters set will
give the population growth dynamics for both types of cells the results of which are shown in the
Fig. 3 and population average of some cell cycle properties for normal cells and target cells are
shown in Table 4. Normal cells have almost equal durations of G1 and (S+G2+M) phases
whereas the target cells have very small duration of (S+G2+M) phase compared to the G1 phase.
The predicted difference in the properties of the two types of cells is due to the assumed
difference in the specific growth rate and rate parameters for the mechanisms of cyclin synthesis
(reaction 1), APC inactivation (reaction 4) and degradation of activating protein (reaction 7).
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Generally, cell cycle phase specific drugs exploit these differences in the cell cycle properties of
normal and abnormal cells and a similar strategy is followed in the current model simulations.
In practice, inhibition by any particular drug of the reaction mechanism in the cell cycle
network depends on the biochemistry of the drug and the genes involved in the mechanism. In
the absence of information about biochemistry of the drug, equal inhibition effect is assumed for
both types of cells for a given action of drug. In some compartmental models, researchers
provide higher selectivity of the drug towards target cells by giving lesser value of cell kill rate
for healthy cells than cancer cells. One such provision can be made in the present model by
adjusting the cell death threshold value for the target cells. To selectively have higher action of
the drug for target cells, the threshold value is reduced in some of the simulations. These are
denoted as the target cells of type 2. There are oscillations that resemble qualitatively the cell
cycle. There is antagonism between APC and cyclin levels.
Table 4: Cell cycle properties for normal cells and target cells
Type of Cell

Mass at
Mass at
Mass after
(S+G2+M)
Cycle
Birth
Division
Division
G1 length
length
Duration
Normal cells 0.163552
0.297337
0.163545
1.473451
1.533916 3.007367
Target cells
0.698833
1.443708
0.713909
1.558247
0.147951 1.699369
target cells
(type 2)
0.562545
1.116099
0.586075
1.624644
0.104821 1.725776
Table 5: Parameters and Trigger values for slow growing populations

Specific growth rate: 0.2
Trigger Values
Number of cyclin/Cdk molecules needed to trigger start: 40
Number of cyclin/Cdk molecules needed to trigger division: 10
Cell mass at which cell is considered dead: 1.25
45

Table 6: parameters and trigger values for fast growing populations

Specific growth rate: 0.4
Trigger Values
Number of cyclin/Cdk molecules needed to trigger start: 40
Number of cyclin/Cdk molecules needed to trigger division: 10
Cell mass at which cell is considered dead: 2.5

Figure 3: Monte Carlo solution of cell cycle model for normal and target cells
4.3.4. Concept of Toxicity
Toxicity of the drug towards normal cells limits the total dosage of the drug that can be
administered in a given treatment period (also known as maximum tolerated dosage – MTD) and
also limits the dosage of the drug at any instance during the treatment (known as dose limiting
toxicity - DLT). Thus, toxicity is incorporated by simulating the effect of drug on healthy cells
also. In the simulated results toxicity is measured in terms of surviving healthy cells fraction. If
the effect of drug action results in reduction of healthy cell fraction more than the acceptable
limits, then it cannot be a suitable drug treatment. This approach is very convenient to handle
multiple toxicities. A single drug can lead to multiple toxicities, for example toxicities associated
with paclitaxel include peripheral neuropathy, neutropenia, alopecia, mucositis, arthralgias, and
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myalgias (Fetterly et al., 2008). If the model parameters are available for different types of cells
related to these toxicities, it is easy to simulate the effect of the drug on those normal cells and
thus to evaluate multiple toxicities in parallel to the tumor response and hence to control the
scheduling and doses of drugs. In the simulation results, toxicity is discussed qualitatively in
terms of the fraction of live healthy cells predicted during the treatment.
4.3.5. Assumptions
1. The model is assumed to be homogeneous in that all the cells are in a highly vascularized
tissue and all these cells will be exposed to the same drug environment. Hence, during the
drug effective period, the reaction parameters affected by the drug are modified with
same value of inhibition factor for all the cells.
2. The drug is assumed to be administered through intravenous injection and it is assumed
to reach the tumor target site instantaneously.
3. Evolution of drug resistance is not considered at this time.
4. In case of multiple drug treatment, synergism between two drugs acting simultaneously is
neglected and the drugs are assumed to have independent effect on cells. For including
such interactions among the drugs, detailed biochemistry is needed which is not
considered in this model.
4.3.6. Reporting the Results of Drug Action Simulations
Simulation results are reported in two different ways. One is the time course of total
number of live cells in the population with or without the influence of drug. The simulations
without the action of drug are referred to as WT (stands for Wild Type) case. In some of the
results, logarithm of the total number of live cells is used for convenience. Expressing the results
in terms of the total number of live cells gives a direct measure of the size of the cell population.
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Another convenient way is to express the results in terms of the time course of proportion of live
cells compared to the WT type case, expressed as the ratio of the total number of live cells after
any time period of a selected drug treatment strategy to the total number of live cells during the
same time when there is no drug action (WT case). This ratio will give the survival fraction of
the targeted cell population from the treatment if this treatment results in the reduction of the
total number of live cells compared to the WT case.
4.4. Results and Discussion
Simulations are designed to demonstrate the usefulness of the model in identifying
treatments that can simultaneously satisfy two important goals of chemotherapy viz.
effectiveness in reducing the tumor size and keeping the toxicity to the normal cellular tissues in
acceptable limits. First, set of reactions in the proposed cell cycle model are identified that can be
used as potential drug targets for the selected cancer cell population. Second, for the drugs
targeting the identified target reactions, various administration strategies are tested for a single
drug by varying drug dosage, time interval between drug injections, and effective period of the
drug. Finally, simulation results are presented for identifying combination of multiple drugs that
are effective in satisfying both efficacy and toxicity requirements.
Effect of treatment on curing the tumor is evaluated by determining the number of tumor
(target) cells and the toxicity is determined by evaluating the number of normal cells after the
treatment. The target reactions are identified in such a way that the treatment strategy satisfies
both the requirements adequately.
Simulation results of the time course of population growth of normal cells and target cells
for continuous inhibition of each of the seven reactions for wide ranging inhibition factors are
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obtained to identify good target reactions. The results of the identification of the target reactions
are presented in the Appendix B.
Based on the results of the identification of target reactions, reactions 4 and 7 are
identified as possible target reactions from the chosen cell cycle reaction network. The drugs that
act on cells by targeting these reactions are denoted as drug 4 and drug 7 respectively. From the
continuous inhibition simulations, the results for drug 7 show that, it is very effective for
continuous inhibition, in selectively killing the target cells leaving the normal cells unaffected. It
is effective even at small dosages and it has the tendency to increase the growth of the normal
cells by speeding up their progression through cell cycle at low dosages. For Drug 4 to be
effective in killing the target cells it should be applied at high dosage which will also severely
affect the growth of normal cells.
Prolonged continuous infusion, however, may facilitate the evolution of drug resistance
by gradual processes such as gene amplification (Gardner and Fernandes, 2003) and also causes
severe toxicity problems and thus chemotherapic drugs are administered in periodic cycles.
Cyclic treatment gives rest intervals for the normal cells to recover as well as for pulling
quiescent cells to proliferating state. The disadvantage is that cancer cells start regrowth and the
treatment duration increases. For that matter, the time gaps between the drug injections, time of
drug exposure, and dose of the drug are important parameters in the treatment design
considerations to achieve greater tumor control while limiting the toxicities. In the next section,
the results of various periodic administration strategies involving drug 4 and drug 7 are presented
that evaluate tumor control and toxicity to normal cells simultaneously.
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4.4.1. Periodic Administration of Drug 4
Same Gap - Dose Variation
For same gap and effective time, dosages (or degrees of inhibition of reaction 4) are
varied and the effect on target cells and normal cells of this treatment is shown in Fig. 4.

Figure 4: Periodic administration of drug 4 for various inhibition factors. Numeric notation (e.g.
0.2,10,5,10) as shown in labels represent inhibition factor, time gap, effective time, drug
injection time.
The total number of live cells is simulated for both types of cells for inhibition factors
0.16, 0.2, 0.232 and 0.3. Simulations are done for effective time = 5 and time gap = 10 with the
treatment started at time = 10. These simulations are similar to the dose escalating experiments
generally conducted in the clinical trials for finding out the dose limiting toxicity (DLT).
From the Fig. 4, live cell fractions for the target cells decreases considerably with
increasing dosage. The fraction drops to 0.05 after treatment time = 20 for 0.16 dose whereas it is
equal to 0.2 for the dose 0.2. Increasing the dose has considerable advantage in killing the target
cells as in the case of continuous inhibition. However, it is interesting to see if periodic
administration helps normal cells to recover in the dug ineffective periods. From the Fig. 4,
normal cell fraction fluctuates from 1 to 0.4 during the treatment time at high dosage of 0.16 and
this fraction further reduces away from 1 as there are some cell deaths observed in these
simulations. Whereas for lesser dosages, this fraction fluctuates around 1 and the deviations are
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small with lesser dosage than the deviations observed for the dosage 0.16. Model predicts no cell
deaths for normal cells for doses 0.2 and higher. The selected gaps at these doses are sufficient
for normal cells to recover and hence their live cell fraction oscillates around 1. Based on the
toxicity tolerance limits, we can either go for high dosage of 0.16 that has severe effect on
normal cells or for a slightly lesser dosage of 0.2 that is not severe on normal cells. Through
these results we demonstrate that the model predictions can be used to find out suitable dosages
for a given periodic drug administration with known pharmacokinetics.
Same Dose - Gap Variation
Time interval between the two drug infusions is another parameter that can be varied to
improve the treatment effectiveness. From the earlier discussion, dose 0.16 was effective in
controlling the target cell population, but it has caused large fluctuations in the normal cell
populations at time gap between injections of10. Simulations are performed by varying the time
interval between the drug infusions for values of 6,8,12 and 15 units and the response of the
normal cells and target cells to the treatment is shown in the Figure 7 along with the response for
gap = 10. Drug injection started at time = 10 and the effective time for drug is kept at 5. WT
(wild type) represents the response of the cells when there is no action of drug.
For same dosage, increasing the gap, its effect on the treatment efficacy is examined. At
the selected dosage, all the target cells have died for gaps 6 and 8. Increasing the gap between the
injections allows cancer cells to regrow and this is reflected in the results for higher gaps shown
in Fig. 5. As the gap is increased to values of 10, 12, 15 increase in the target cell population is
evident. However, there will be maximum tolerated toxicity (MTD) for any drug limiting the
amount of drug that can be given in a single day. If such limitations exist on the periodic
administration of the drug, more frequent injection (small gap between the successive injections)
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may not be possible. The effect of gap on the normal cell population is also shown in Fig. 5.
Simulations predicted no deaths of normal cells for gap of value 6 and some deaths for all the
higher gaps. As long as the gap does not result in any cell deaths, normal cells oscillate around
the average value of around 0.8. This is better than the case of continuous inhibition at the same
dose where live cell fraction for normal cells is maintained closed to 0.6 as in Fig. 5(b) of
Appendix B without any cell deaths. As the gap is increased between the injections, some cell
deaths have occurred resulting in a constant drifting away of the total live cell fraction from
average value. Since periodic injection at dose 0.16 with small gaps is causing target cells to die
and normal cells to have fewer oscillations around mean value, more frequent periodic
administration of drug 4 is preferred to a less frequent administration with large gaps. Again, if
there is a problem with the frequent application because of the portability of the drug injection
equipment, these simulations help us to identify periodic administration strategy with the next
best suitable gap.

Figure 5: Periodic administration of drug 4 for various time gaps between drug injections
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For continuous administration for same dosage, all the target cells are dead as observed in
simulations (not shown here), but normal cells have live cell fraction close to 0.6. By employing
periodic drug administration, the impact on normal cells is reduced. The above results show that,
keeping the frequency of drug administration high will keep the effectiveness of the treatment
closer to that of continuous administration.
Different Doses - Different Gaps
Sometimes, it is important to decide on how to distribute a total dosage in periodic
administration. Weather to apply the drug in more frequent intervals with less dose each time or
to apply the drug less frequently with large dose each time. Generally, AUC is used to find out
the combinations of dose and frequency each giving rise to same total dosage over a total
treatment time. Simulations are performed for various dose – frequency combinations to study
their effect on cancer and normal cells. From the Figure 8(a), high dose (0.16) of drug 4 for less
frequent injection is effective than small dose (0.232) with more frequent (continuous) injection.
From Figure 6(b), more frequent injection at smaller dose (0.2) will be better than high dose
(0.16) of drug at large gap between the injections for normal cells. Considering both toxicity and
effectiveness of the drug 4, the intermediate dose 0.2 appears to be preferable to the other two
doses (0.16 and 0.232).
From Fig. 4, dose of 0.2 is better than the dose of 0.16 from the toxicity point of view.
For killing the target cells, 0.16 dose is preferred to 0.2 dose. Considerable improvement for 0.2
dose is obtained by reducing the gap from 10 (Fig. 4) to 7 as in Fig. 6. More frequent injection at
dose 0.2 has improved its effectiveness while keeping its toxicity to normal cells acceptable.
Through this model, it is possible to find out suitable dose-frequency combinations that can
simultaneously satisfy the requirements of reducing the cancer burden and reducing the toxicity.
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(a)

(b)

Figure 6: Dose frequency combinations of administration of drug 4
Effect of Drug Decay (Half Life)/Drug Pharmacokinetics
All the previous results are presented for continuous inhibition without considering the
pharmacokinetics of the drug in the body. Fig. 7 shows the results for administration of drug 4 in
periodic pulses accompanied by exponential and linear drug decay instead of periodic
administration with constant inhibition.

Figure 7: Periodic administration of drug 4 with linear and exponential decay
A dose of 0.16, gap of 10, effective time of 5 are considered and drug is administered at
time = 10. For the selected effective time which indirectly signifies the half-life of the drug, this
treatment has negligible effect on the target cell population for both types of drug decay. To have
its effect, the drug should act for longer effective times in the body. In other words, half-life of
the drug in the body should be very high. Fig. 8 shows the results for drug 4 with longer effective
time of value 20, where there is not much effect on normal cells (Fig. 8(b)). There is not much
inhibitory effect on target cells for exponential decay of drug 4, only linear decay case shows
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some improvement with higher effective time (Fig. 8(a)). Thus, drug 4 may not be an effective
choice when its pharmacokinetics is such that its action stays for less time in the body. These
dependencies on pharmacokinetics suggest better formulations of this drug that will allow drug
to stay for longer times in the body.

(a)

(b)

Figure 8: Periodic administration of drug 4 with linear and exponential decay with increased
effective time of drug
In the case of drug 4, the less effectiveness is due to the less retention time of the drug. If
there was drug for more time, as in the case of uniform drug infusion, efficacy was more. So, the
drug should be designed in such a way that there will be more retention time for the drug.
4.4.2. Periodic Administration of Drug 7
In the case of drug 4, pharmacokinetics played an important role in the effectiveness of
the drug in killing the cancer cells. Drug 4 was needed to stay for a long time in the body to show
its effect on target cell population. Similar simulations to see the influence of pharmacokinetics
on the effectiveness of the drug 7 in killing the target cells are performed at the dosage 0.6.
Separate simulations are carried out for exponential, linear and no decay of the drug 7 with time
gap = 10, effective time = 5 and injection starts at time = 7. The results of the simulations are
shown in Fig. 9. Fraction of the live target cells predicted in the case of no decay of the drug is
less compared to the cases when exponential and linear decay are considered. However, for both
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the cases of drug decay, unlike for drug 4, there is considerable decrease in the fraction of the
target cells in the periodic treatment for drug 7.

Figure 9: Efficacy of drug 7 with exponential and linear decay compared to no decay
The amount of time drug stays in the body was enough to bring in a reduction in the size
of the target cell population. In Fig. 10, fraction of cells with the exponential and linear decay for
high dose of 0.3 is compared with the no decay case of drug 7 acting at low dose of 0.8.
Increasing the dose of the drug has compensated for the lesser retention time due to the drug
pharmacokinetic effects and the efficacy is more compared to the no decay case. Normal cells
are not affected by this increase in the dose. These results demonstrate the differences in the
effectiveness of the two drugs, drug 4 and drug 7 with different pharmacokinetic properties in
killing cancer cells.

Figure 10: drug decay with increasing dose of drug 7
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Dose - frequency simulations are performed for drug 7 as it is done for drug 4. For a drug
effective time of 5 units, doses of 0.6, 0.75 and 0.8 are applied for 11 gap, 7 gap and continuous
injection respectively. These values have been selected arbitrarily and the purpose is to
demonstrate the use of the model for the case of drug 7 for various dose-frequency combinations.
From the Fig. 11(a), 0.6 with gap 11 has high efficacy compared to the other high dose cases
with frequent injection. However, the continuous injection of dose 0.8 is slightly better than the
treatment with higher dose 0.75 with gap 7 between the injections. Since, the exact relationships
are not defined for dose and the amount of inhibition it is not possible in the present model to
choose the gaps and dose in a way to conserve the total amount of dose for a specific length of
treatment period. As a consequence of this, the efficacies may vary for a different set of gaps for
the chosen doses. For example, in the Fig. 11(b), simulation results for target cells of type 2 are
presented for the same doses (0.6, 0.75, 0.8), but, with different set of gaps between the
injections. From Fig. 11(b), frequent injection of drug 7 with dose 0.8 gives high efficacy than
the other two cases which are more or less equally effective in killing the target cells. Combining
such predictions from the model with the practical considerations like portability issues will
result in best choice among a variety of dose-frequency combinations.

(a)

(b)

Figure 11: Dose frequency combinations of drug 7 on target cells (a) and target cells of type 2(b).
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Periodic Administration - Drugs Targeting Reactions 5 and 6
From the continuous inhibition simulations, it was seen that drugs targeting reactions 5
and 6 are less effective in killing target cells at low doses but at higher doses those drugs affect
normal cells also. Periodic administration strategies may ease the toxicity as is observed in the
case of drug 4. Simulation results for the case of periodic administration of the drug 5 and drug 6
are shown in the Fig. 12.

(a)

(b)

(c)
Figure 12: Effects of periodic administration of (a) drug 5 on target cells (b) drug 5 on normal
cells and (c) drug 6 on both target and normal (shown as slow on the legend) cells.
All the simulations are done by starting the drug injection at time = 10 and effective time
= 5. At doses 0.7, 0.75, 0.725 the fraction of target cells does not drop much with the periodic
treatment, but the efficacy of the drug improves if the dose is increased to 0.6. At the doses
0.725, 0.75, fraction of the normal cells stays close to 0.8 during the drug effective time and the
cells recover to the actual population size during the gap between the successive injections. As
the drug dose increased to 0.7 and 0.6, normal cells are also killed with the treatment which can
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be observed by the gradually decreasing fraction of the normal cells with the treatment time.
Similar result is obtained for periodic inhibition of the reaction 6 as shown in Fig. 12(c). At small
dosages, there were not many target cells killed (results not shown here) and at the dose of 0.6,
fraction of cells for normal cells is very less and the drug acts almost as severely on normal cells
as it does on target cells.
These simulations suggest that treatment strategies by compounds that target reactions 5
and 6 cannot be advisable from the considerations of their toxicity to normal cells. Hence, the
present modeling approach based on the regulatory mechanisms controlling the division cycle of
cell populations will give insights to the drug developers on what pathways to target and what
pathways not to target for cell cycle based chemotherapy.
Combined Action of Two Drugs
Conventionally, most of the chemotherapic drugs are administered in combination with
other drugs to increase the effectiveness of the treatment. The present model is easily extended to
include the action of multiple drugs. In the absence of detailed biochemistry of the drugs, it will
be difficult to include any interactions among the drugs which can affect the overall inhibition
effect by the combined action of the drugs. Hence, it is assumed that the inhibitory effect of any
drug on a particular reaction is independent of the action of any other drug on the same reaction.
Simulations are performed for the case of continuous inhibition, to demonstrate the combined
effect of two drugs targeting different reactions. Corresponding rate constants are multiplied by
inhibition factors to represent each drug action. Fig. 13 shows the examples of drug
combinations for continuous drug administration where both drugs act synergistically in
improving the efficacy of the treatment by killing more number of target cells than their
individual drug action. Their combined effect results in negligible effect on the normal cell
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population. In Fig. 13(b), drugs 4 and 7 are combined with doses 0.3 and 0.85 respectively. In
Fig. 13(a), drug 6 and 7 are combined with doses 0.8 and 0.85 respectively. In both the cases,
live cell fraction of normal cells stayed close to 1, whereas the combined effect of treatment on
target cells is highly significant.

(a)

(b)

Figure 13: (a) Combined effect of drug 6 and drug 7 on target cells and normal cells; (b)
Combined effect of drug 4 and drug 7 on target cells and normal cells.
A different scenario where the combined action of drugs does not show significant
improvement in the treatment is shown in Fig. 14. In Fig. 14(a), Drug 5 and Drug 4 are combined
with doses 0.75 and 0.3 respectively and this combination does not succeed in reducing the target
cell population even though the live cell fraction of normal cells stays close to 1. For the
combination of drugs and doses shown in Fig. 14(b), (drug 5 and Drug 6 are combined with
doses 0.8 and 0.8 respectively), both normal cells and target cells are affected severely and thus
this combination cannot be used for a successful treatment.

(a)

(b)

Figure 14: (a) Combined effect of drug 5 and drug 4 on target cells and normal cells; (b)
Combined effect of drug 5 and drug 6 on target cells and normal cells.
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4.4.3. Summary of the Results
Continuous inhibition of each reaction in the cell cycle network is simulated to identify
target reactions. Drug 4, Drug 7 which indirectly contribute for keeping active APC at higher
levels by inhibiting reactions 4, 7 respectively in the cell cycle network are identified as suitable
for controlling the selected tumor type. Such predictions about target reactions for drugs will be
helpful in development of new drugs targeting those pathways. These simulations are not only
helpful in identifying target reactions, but also helpful in finding out the limits on the dosage of
drugs. These are similar to the dose escalation studies performed in clinical trials. However,
continuous inhibition simulations also reveal the effect of cell cycle specific drugs on normal
cells which is a measure of toxicity and suggest periodic drug administration. Periodic
administration allows cells to recover in the gaps between successive drug injections. Using drug
4 and drug 7, periodic drug administration strategies are tested by varying drug dose, gap
between the injections, different dose – gap combinations and by including drug
pharmacokinetics for both drugs 4 and drug 7. The results for suitability of other drugs reveal
their ineffectiveness even when periodic administration is considered. Same model is used to
find the combination of drugs that can work in synergy to cure tumor without affecting normal
tissues. Continuous inhibition simulations are performed on both cancer and normal cells for
synergistic action of drug combinations.
4.3. Conclusions
A chemotherapic model is developed based on stochastic chemical kinetics of cell cycle
regulatory network and Monte Carlo simulations are used to compute the time course of the
growth of cancerous and healthy cell populations in response to chemotherapic treatment. Effect
of drug is included in the model by inhibiting one of the reactions that are crucial for regulating
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the cell cycle progression. This approach helps in predicting the action of multiple drugs on
tumor cell growth. Toxicity is considered by simulating the inhibitory effect of drug on healthy
cell population growth. By including the effect of the drug action on the growth of both healthy
and cancer cells, the model demonstrates the pathway to determine favorable treatment strategies
for varying dosages, drug effective times and time gaps between drug injections. A simple linear
or exponential decay of the drug is included in the drug testing simulations.
Model‟s predictability is helpful and useful in clinical trials to identify administration
strategies that are best suited to each individual. If the parameters are obtained from the patient
specific biopsies, tailoring treatments to each individual is possible. If the parameter space is
available that represents a population of random patients, this model can predict the result of
drug treatment for each such combination of parameters which averaged on the whole population
gives probability of cure for a specific drug during the drug development stage. Hence, in silico
screening of drugs is possible with the present modeling approach.
Compared to many deterministic models available in the literature, the present stochastic
formulation has the benefits of dealing with intra-patient variability. – Tumors are associated
with variability among cell population and each of them will respond independently to
chemotherapic drugs which is an important factor when cell cycle phase specific drugs are used.
Cell cycle specific drug action is easily handled in the current modeling formulation as
the model is based on the progression of the cells through cell cycle. However, cell cycle nonspecific drug action also can be easily implemented. Cell cycle non-specific drugs target genes
(for example p53) that act outside the cell cycle, which are involved in DNA damage, apoptosis
pathways. By simply adding another module that includes these reaction networks, it is easily
possible to link the cell cycle to the extra-cell cycle regulatory network and checkpoint
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mechanisms in the stochastic chemical kinetics formulation. This is similar to the integrated
approach described in Ribeiro & Pinto (2009) except that they followed deterministic approach.
The present modeling approach is very useful as it follows an integrated methodology in
which multiple modules can be added independently. In the present study, a simple cell cycle
model representing a model eukaryotic organism is used. A more detailed and more realistic
reaction network can be used in future work. Similarly, it is easy to use different drug
pharmacokinetics in place of simple linear and exponential decay. Single and multiple
compartmental models are generally used to represent various barriers for representing drug
transport from the drug intake till it acts on its gene target on the cellular and subcellular region.
Similar provisions are possible for modifying drug pharmacodynamics by incorporating well
defined correlations between the dose and degree of inhibition of the target reaction such as
Emax, sigmoidal relationships. Another important module in the integrated model is the genetic
resistance to the acting chemotherapic drugs. It is not considered in the present model in its
preliminary stage. It can be incorporated as another module. Gene amplification, random
mutations to the genes involved in drug metabolism and alternate metabolic pathways are
identified as some of the possible mechanisms for evolution of drug resistance. These genetic
interactions and reaction pathways can be combined with the cell cycle network as another
module for describing drug resistance. The effect of drug on cells manifests in terms of the
reduced inhibition factor of the selected drug on its target reaction.
With the current approach it is possible to evaluate toxicity and tumor control
independently which is useful considering the fact that each patient will have different objectives
and concerns (i.e., cure or palliation) related to the treatment. Also, there are many types of
toxicities viz. neurological, cardiac, gastrointestinal in addition to the toxicity to the blood stem
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cells that may affect the treatment (Gardner and Fernandes, 2003). These toxicities can be
handled by using parameters specific to the corresponding normal tissues, in the tumor growth
model. Using this methodology, we do not have to resort to simultaneous optimization of toxicity
and tumor cell kill as described in optimal control models of (Swierniak et al., 2003) where only
one type of toxicity is considered.
Through the present model, simultaneous action of multiple drugs can be tested by
making changes to inhibition factors of their respective target reactions in the cell cycle reaction
network. One way to obtain the exact relationship between drug dose and resulting inhibition
factor is by combining drug kinetics with the cell cycle network as is done by Chappel et al.
(2008) using a deterministic formulation. Any interactions among the drugs acting
simultaneously is not considered at the moment, as it demands more biochemical details and
reaction kinetics of drug molecules.
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CHAPTER 5. SELECTION OF MODEL PARAMETERS
5.1. Introduction
5.1.1. Background and Motivation
Parameter estimation for stochastic models needs a special consideration. One way of
finding the stochastic model parameters is by using the rate parameters obtained from
deterministic models. Deterministic models are fit to experimental data by classical least squares
optimization tools to obtain the rate parameters and these can be converted to the equivalent rate
parameters for stochastic kinetics. However, such conversions are not always possible, especially
when the rate expressions are not in the form of simple mass action kinetics. Another issue is that
stochastic kinetic models of a given reaction network will have more model parameters than the
deterministic model of the same network. All the reaction propensities must be determined to
complete the model. One possibility to determine these parameters is by fitting the model to
transient distribution of reactant molecules which can be used to estimate the parameters of the
stochastic model. Since there will be large number of species involved in most of the
biochemical networks, real time measurements of molecular concentrations for large enough
number of cells is needed to calculate the required transient distribution. Obtaining such a huge
amount of real time data is not always an easy task.
An alternative strategy is to fit the model to steady state distributions of states of cell
population that can be easily obtained from flow cytometry measurements. Obtaining the
property distributions for cell population from Monte Carlo simulation of the present stochastic
cell cycle model is described earlier. The distributions obtained from the model will depend on
the values of the reaction propensities and other model parameters. Thus, biologically reasonable
values of the model parameters can be obtained by fitting the model to the distribution of states
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obtained experimentally using the usual least squares techniques. This is a well-known technique
applied for DNA distributions (Dean and Jett, 1974; Johnston D. A., 1978; Bailey, 1981). Fitting
the distributions to models with large number of parameters is a challenging problem as it may
result in over fitting. Thus, a wise strategy is to seek the solution of least squares problem in
terms of only those parameters that have considerable impact on the distributions. In the present
work, a method is developed that will be helpful in identifying the importance of different
parameters on the observed distributional properties and also helpful in obtaining a good starting
guess of the parameters for the least squares problem.
Budding yeast Saccharomyces Cerevisiae is considered as model organism for eukaryotic
cell cycle studies and the characteristics of its cell population distributions are widely
understood. The gene regulation and biochemical pathways related to cell cycle progression of
yeasts are similar to those found in higher eukaryotes. Thus, logical step to handle the parameter
selection problem for stochastic models is to start with the distributions of budding yeast cell
populations and then to extend the understanding to higher organisms.
5.1.2. Objective
The main objective of the current chapter is to present a methodology to refine the basic
cell cycle model described earlier such that the population characteristics derived from the model
resemble the characteristics of budding yeast cell populations and to implement a parameter
selection algorithm that selects values of the parameters that optimize a specific characteristic of
the population derived from the model. Specifically an evolutionary optimization strategy,
termed here as insilico evolution is proposed that selects the stochastic model parameters
representative of a cell population with largest growth rate.
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The idea of selecting parameters that optimize a particular property of distributions is
developed similar to the idea of flux balance analysis (FBA) that has been widely used in
metabolic pathway analysis (Schilling et al., 2000; Orth et al., 2010). The objective of FBA is to
select the optimal distribution of metabolic fluxes of each reaction in the network to maximize a
phenotype or production of a particular metabolite. There might be many combinations of the
individual reactions that give optimal solution. The range of values of contribution from a
specific reaction gives the sensitivity of the objective function to changes in fluxes from that
reaction, which is determined by flux variability analysis. In the present work, insilico evolution
is employed as the optimization strategy to select the combination of parameters contributing to a
maximize population growth rate. Maximum population growth rate of cells can be easily
obtained from the cells growing in exponential phase.
Insilico evolution is initially applied to the basic cell cycle model to gain insights into the
salient features of the proposed methodology. The stochastic cell cycle model is then
reformulated to include more realistic features of budding yeast cell population. To make the
model more realistic, model parameters with arbitrary units are assigned proper units of mass
and time based on the comparison of properties of distributions obtained from the model with
those collected from the literature data. At this stage, the model with its realistic parameters is in
a more refined form than the basic model. The insilico evolution is then applied on the refined
model to improve the values of model parameters corresponding to cells with maximum growth
rate.
5.2. Parameter Selection by Insilico Evolution
The insilico evolution method which is described in the next section requires initial set of
model parameters that give cell cycle oscillations. To obtain the initial set of parameters, a
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systematic approach to tune the stochastic cell cycle model parameters to cause oscillations,
characteristic of cell cycle dynamics, is discussed by Sherpa and Hjortso (unpublished work) and
the parameter set used in the basic cell cycle model is obtained from the same approach which is
briefly explained here. First, reactions that are not essential for onset of oscillations are turned
off. Even though a rigorous mathematical analysis is possible using center manifold analysis, this
process can be carried out by inspection for simple reaction networks. The rate constants for the
still active reactions are then determined by turning off all reactions except those determine the
dynamics in the early part of the cell cycle. Reaction parameter values are adjusted by hand until
one obtains a response that is in qualitative and, to the extent possible, quantitative agreement
with experimental observations. Reactions that determine the dynamics of next sequence of
events in the cell cycle oscillator are then turned on and their associated parameters adjusted by
hand as before. This continues until all reactions are activated at which point the model oscillates
and the parameter set is ready to be used in the insilico evolution algorithm.
5.2.1. Insilico Evolution Algorithm
The final parameters obtained from the insilico evolution will result in cell cycle
oscillations and represent the cells with maximum population growth rate. The description of the
algorithm is as follows.
The basic idea of the insilico evolution is built on the process of natural evolution.
Initially, there will be a specified number of cells in the system all having the same set of
parameters of the cell cycle model.
The parameters of the model which affect the propensities of various cell cycle pathways
are perturbed randomly (characteristic of mutation) at each cell division and each of the newly
born cells will get two different sets of perturbed parameters and their growth is described based
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on the new set of model parameters. The extent of perturbation (or mutation) of the existing
value of any parameter depends on the mutation rate which is assumed to take values between 0
and 2, where a value of 0 corresponds to no mutation and a value of 2 corresponds to maximum
range of possible mutated values which is double the magnitude of the parameter value. The
perturbation of the parameter is related to the mutation rate by the following expression which is
schematically represented in the Fig. 15.

Where,

represents the parameter after division and

represents the parameter

before division occurred. The „random number‟ is a real number uniformly distributed in the
interval [0,1].
After the population increases to a pre-specified size, some cells will be
eliminated from the system to bring the population back to the original size and the process of
mutation and elimination of the cells is repeated. After many repetitions of the procedure, cells
that have a low population growth rate and maximum likelihood of death will be eliminated and
the existing cells in the system will have a high population growth rate. The set of parameters
corresponding to the existing cells are selected as the improved parameters compared to the
initial parameter set that gave oscillations.

Figure 15: Schematic explanation of “mutation rate” applied to model parameter (“k” as
illustration)
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5.2.2. Linking Perturbations in Parameters to the Change in Population Growth Rate
During Insilico Evolution
Perturbations to the parameters of the cell cycle model influence the cell cycle
progression. By knowing the relationship between cell cycle progression and the single cell
specific growth rate, it is possible to relate the perturbations in the parameters and the resulting
effect on the population growth rate. For zero order single cell growth kinetics, specific growth
rate of cell continuously changes during the cell cycle from maximum at the start to minimum at
the end. Based on this fact, a population with smallest average cell mass will have highest
population growth rate. Hence, by assuming zero order growth kinetics of single cell, parameters
corresponding to the lowest possible cell mass in the evolution can be selected as those giving a
population of maximum growth rate.
5.2.3 Insilico Evolution Simulations
In the present work, all the simulations of insilico evolution are started with 100 new
born cells and 10 cells are selected randomly and eliminated from the system once the total cell
population reaches a number of 110 cells. These simulations are performed till 10000 iterations
whenever possible to resemble the natural evolution in which new traits occur due to mutations
over many generations.
Evaluation of the Algorithm
To evaluate the algorithm, it is tested with an initial condition of an equal number of fast
growing and slow growing cells and a zero mutation rate. For this system, the algorithm should
select for the faster growing cells and eventually eliminate the slower growing population
completely. These cells are classified as slow growing and fast growing cells based on the
difference in their doubling times.

Different values to one of the cell cycle parameters
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(Parameter k4 in this case) are assigned to these cells growing in zero order kinetics. The cell
cycle properties of these two types of cells are listed in Table 7. The differences in the values of
cell mass after and before cell division highlight that fast growing cells divide at lower cell mass
than the slow growing cells which is expected when zero order single cell growth kinetics are
used.
Table 7: Fast and slow growing cells
Average values
mass at birth

Fast Cells
0.403929

Slow Cells
0.497314

mass just before division
G1 duration
G2 duration
Doubling time
Reaction parameter, k4

0.807758
2.01007
0.009074
2.019144
400

0.99277
2.462842
0.01444
2.477282
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The results of insilico evolution are shown in Fig. 16 in terms of number of fast cells and
slow cells in the system which started with 50 cells of each type. When 10 cells are randomly
eliminated from the system, only fast growing cells remain after 146 iterations eliminating all the
slow cells. These results give confidence in the effectiveness of the insilico evolution algorithm
in selecting cells with maximum growth rate.

Figure 16: Evolution of system into fast growing cells and elimination of slow cells in insilico
evolution
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5.2.4. Application of the Insilico Evolution for the Basic Cell Cycle Model
Insilico Evolution Results for a Single Mutation Rate
The insilico evolution algorithm is then applied to the basic cell cycle model to get
insights into the parameter selection problem which can be used to the refined budding yeast cell
cycle model discussed later. Simulations are carried out for different mutation rates. Results of
average values of the parameters and cell mass for the 100 cells remaining after each iteration of
the insilico evolution for a mutation rate of 0.4 are shown in Fig. 17.
For this mutation rate, convergence in mass was reached rapidly around 2000 iterations.
All the rate parameters, after initial transient, will continue fluctuating even after the cell mass
has converged. These fluctuations are very high for some parameters and are small or moderate
for some parameters and some parameters remain constant with negligible fluctuations. These
fluctuations in the parameters can be seen as different combinations that give same optimal
solution as is done using flux balance analysis (FBA) of metabolic networks. From the Fig. 16,
parameter k1 reaches a very high value compared to the initial value it was started with.
Parameters k1 and k4 change up to magnitude of 10 times, whereas parameter k5‟‟ changes up to
several orders of magnitude. The parameter Nx converges to a constant value of 2 and remains
constant. The insilico evolution simulations qualitatively perform sensitivity analysis of the
model parameters. The parameters that fluctuate to large extent will have less effect on the
population distribution than those parameters that fluctuate by small amount. However, the
magnitudes of these fluctuations are very high for the parameters shown in Fig. 17. It is not
convincing to think that they are different combinations of parameters giving the same optimal
solution. It happens when the rate at which mutations to the parameters are occurring is very
high compared to the rate at which the change is occurring in the population in terms of growth
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rate. Simulations results from two different mutation rates are compared to gain some insights
into these aspects.

Figure 17: Insilico evolution simulation results for Zero order kinetics, mutation rate 0.4, The
starting values for the parameters are, k1 = 800; k4 = 280, k5” = 200.
Influence of Mutation Rate in Insilco Evolution
Simulations are performed for different mutation rates ranging from very small to high
mutation rates. At higher mutation rates, all the cells are died in very small number of iterations.
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Results for some mutation rates of 0.4 and 1.2 are presented in Fig. 18. It appears that the
convergence has reached at around 2000 iterations for mutation rate of 0.4 and it has not yet
reached for the rate of 1.2 even after 5000 iterations. There is still some transient in the average
mass curve for mutation rate of 1.2. The value of parameter k1 when the cell mass is close to the
convergence value appears to be 10000 for mutation rate of 0.4 and then it has increased to large
values.

Figure 18: Effect of mutation rate on convergence to the final solution.
After reaching the convergence for the rate 0.4, further perturbations to the parameter k1
did not cause any improvement in the value of optimum cell mass. Hence, the selection process
is not in pace with the mutation process. For the case of high mutation rate of 1.2, even for large
fluctuations, there is still some transient in the cell mass. The selection process is still responding
to the large changes in the parameter values suggesting that there should be a definite
relationship between mutation rate and selection pressure. Selection pressure can be defined
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simple terms as the ratio of maximum specific growth of an individual in the population to the
average specific growth of all the cells.
The concept of mutation and selection in the present case can be explained as followed.
There are two rates of changes in the system, one is the rate of change of parameter values and
another is the rate of change in the population composition in terms of specific growth rate of
each cell. The rate of change of parameter values can be viewed as characteristic rate of mutation
and the rate of change of population composition can be viewed as characteristic rate of
selection.
If the characteristic rate of mutation is significantly higher than the characteristic rate of
selection, then the selection process cannot keep up and there is chance of best traits being lost in
the evolution. This should result in traits that are not the best possible. In the current optimization
problem, the best trait we are looking for is the maximum population growth rate which is
reflected in minimum average cell mass of the cells in the system, and if we compare the values
of the converged mass for low mutation rate and high mutation rate, the above point is reflected.
Average cell mass for low mutation rates is less compared to that for high mutation rate and this
difference increases with the difference in the mutation rates.
Only if the mutation rate is slow enough does the selection process have a chance to have
an effect and only then do we see meaningful results. If the characteristic rate of mutation is too
high, there is danger of extinction of the species in the evolution. Similar results are reflected in
the present scenario of parameter selection through evolution. For the simulations started with
high mutation rates, the initial perturbations in parameters caused lot of cell deaths and the
insilico evolution ceased soon. Hence, it is a matter of further investigation to quantify the
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mutation rate and selection rate so that mutation rate can be adjusted in the evolution process to
match the selection rate.
5.3. Refining the Basic Cell Cycle Model
5.3.1 Model Description
With the insilico evolution algorithm working properly, the next logical step is to start
with realistic parameters that lead to population characteristics that are close to the
experimentally observed values. A literature survey on yeast models and experiments to identify
properties characteristic of the yeast cells is done (Hartwell, 1974; Hjortso and Bailey, 1982;
Barberis et al., 2007; Di Talia et al., 2007; Barik et al., 2010; Bryan et al., 2010). Many
observations are made in the literature regarding the cell division of budding yeast and some of
which are mentioned below. A schematic of the cell division model based on these observations
is shown in Fig. 19.

Figure 19: Schematic of the model of cell division in budding yeast
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M: cell cycle time of mother cell
D: cell cycle time of daughter
m0: mass of daughter cell immediately after cell division
m*: critical mass (cell mass required for start event to occur)
md: cell mass at the time of division


Mother cells will divide into a new cell of mass close to a constant value known as
critical cell mass and the daughter cell will obtain a mass less than critical cell mass.



The mother cell cycle time is roughly constant, independent of growth conditions, while
the daughter cell cycle time varies strongly withy growth rate, being shorter at higher
growth rates and longer at lower growth rates.



The start event which is considered as the checkpoint for starting the DNA synthesis, will
not occur until the critical cell mass is reached.

The stochastic model is modified to incorporate these changes. The modifications are as
followed.


The “start event” will not occur until cell grows to the critical mass in addition to the
condition of the earlier model in which start event occurs only after cyclin/Cdk molecules
reach a threshold value.



Cell will not divide until it attains a mass that is at least equal to the sum of critical cell
mass and minimum required cell mass. Earlier condition is for the cell to attain a mass
that is double the minimum mass.



At the time of division, partition of the total cell mass occurs in such a way that mother
cell will attain a cell mass equal to critical cell mass and daughter cell gets the remaining
mass.
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Daughter cell will not synthesize any cyclins until it reaches the size of the critical cell
mass. This provision is to prevent multiple oscillations during the cell cycle of daughter
cell before the threshold value of mass for division is reached as shown in the Fig. 20.

Figure 20: An erroneous behavior of multiple oscillations of daughter cell in cell cycle
5.3.2 Evaluation of the Refined Model
The qualitative behavior one should observe with this kind of model is that the mass
distribution obtained for the cell population should give a curve with double peak with the
distribution shifting towards lower cell mass at lower growth rates and moving to higher cell
masses at high growth rates with almost unimodal distribution. The results depicting the same
behavior are as shown in Fig. 21. Here, parameter „nu‟ is the specific growth rate of single cell
that is used in the cell cycle model simulations with first order kinetics.
At very low specific growth rates, a large fraction of the population consists of cells of
small cell mass and as the specific growth rate is increased, distribution shifted towards higher
cell mass. The second peak in the above distribution occurs at the exact value equal to 0.88,
which is the critical cell mass chosen, at all the specific growth rates. In practice, this peak will
not occur at a fixed value for all the growth rates, instead it shifts towards right as the growth rate
is increased. To include such realistic behavior, value of the mother cell mass is not taken exactly
as critical mass; instead it follows a probability distribution centered on critical cell mass.
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Figure 21: Mass distribution for various specific growth rates; at the time of division, mother cell
attains a mass equal to critical cell mass and the daughter cell gets the remaining mass.
A simple 4th order algebraic equation is used to get the distribution of mother cell mass at
the time of division which is given by the following equation.

Where,

= lower bound for cell mass =
= upper bound for cell mass =
= Maximum allowed deviation of new cell mass from the value of

critical mass
= critical cell mass
= area of the curve

in the interval

The results for the modified model are presented below in Fig. 22 for various growth rates.
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Figure 22: Mass distribution for various specific growth rates, mother cell divides exactly
according to a probability distribution centered on critical cell mass
Apparently, the peak on the right side of the distribution shifts towards higher cell mass
rather than staying at the critical cell mass, as the specific growth rate is increased which is
reasonable with the realistic budding yeast cell mass distributions.
For higher specific growth rates, it is observed in the simulations that daughter cells will
attain larger mass than the mother cell at the time of division which is not reasonable. Thus, the
specific growth rate should be limited to some value above which it is not feasible to have a
biologically reasonable distribution.
5.3.3. Assigning Units to the Parameters
Another step towards making the model more realistic is to assign reasonable parameters
with units assigned to the rate parameters. The approach to adjust the parameters in such a way
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that the simulation results match the experimental data is to compare specific properties of the
distribution obtained both from experiments as well as from the model simulations and to use
this comparison as to estimate the values of the model parameters. The two properties of the
distribution that are used for obtaining units to the initially dimensionless parameters are average
cell cycle time of mother cell and the critical cell mass of the cell population. It is proposed and
experimentally verified in an earlier study that cell cycle times of mother cells are almost
constant at the time of division, whereas variability exists among the cycle times of daughter
cells (Hartwell and Unger, 1977).
Value of average cell cycle time of mother cells is calculated for dimensionless
parameters and equated to the experimentally observed values to obtain the conversion factor for
arbitrary time units to minutes. Similarly, the critical cell mass of mother cells is equated to the
average cell mass of the distribution of cell masses to obtain the conversion factor for cell mass.
Values of critical cell mass and the constant mother cell generation time are taken from
the experimental data of (Hartwell and Unger, 1977).
Average volume of the newly born mother cell at the time of division = 79.4±15.2 µm3.
Approximate value taken in the calculations = 80 µm3 = 80×10-12 cc
Density of yeast is taken as 10% more than that of water
Density of yeast cell = 1.1 g/cc
Average mass of a mother cell at the time of division = 80×10 -12 cc × 1.1 g/cc = 0.88 pg
(pico gram)
Approximate value for the mother cell generation time = 135 time (Hartwell and Unger,
1977)
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Simulations are carried out for the parameters used in the basic cell cycle model. The
properties of the distribution for the arbitrary units (AU) using first order kinetics and zero order
kinetics are given below.
First order kinetics
Average cell mass from the distribution = 0.35 mass AU
Mother cell generation time (or cell cycle time) = 1.65031 time AU
Specific growth rate,

= 0.2 time-1

Conversion factors:
0.35 AU = 0.88 pg (pico gram)
1.65031AU = 135 min
Zero order kinetics
Average cell mass from the distribution = 0.324417 mass AU
Mother cell generation time (or cell cycle time) = 1.62 time AU
Specific growth rate = 0.2 (mass AU) (time AU)-1
Conversion factors:
0.324417 AU = 0.88 pg (pico gram)
1.62 AU = 135 min
Resulting parameters for both the kinetics are shown in Tables 8 & 9.
Table 8: Parameters and growth rate for zero order kinetics
min-1 pg-1
min-1
min-1
min-1 pg-1

min-1
min-1
min-1
min-1

min-1
= 0.00651pg min-1
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Table 9: Parameters and specific growth rate for first order kinetics
min-1 pg-1
min-1
min-1
min-1 pg-1

min-1
min-1
min-1
min-1

min-1
= 0.002445 min-1

5.4. Insilico Evolution Simulations for the Modified Model with Units
Insilico evolution algorithm is now applied for the updated model of the basic cell cycle
model. All the cell cycle parameters are given units as shown in the conversion calculations
earlier. The parameters used in the simulations are as shown in Table 9. Simulations are carried
out for different mutation rates varying from low 0.2 to high range 1.0 and the results are
presented below and discussed.
5.4.1 Results and Discussion
Average mass of cells in the system stays constant after sufficiently large number of
iterations of insilico evolution for different mutation rates. Fig. 23 shows the convergence of
mass for two mutation rates, one is a low rate 0.2 and another is a higher rate 0.4. Convergence
reached quickly (around 2000 iterations) for low rate compared to the higher rate (around 3000
iterations). The idea behind the insilico evolution is based on the linking of growth rate to the
cell mass using zero order growth kinetics. For zero order kinetics, the smaller the mass of the
cell, the higher is its specific growth rate. Thus, when the convergence in mass is achieved
during the insilico evolution, the cells in the system have reached maximum possible growth
rate. In the later discussion, the term “convergence” used frequently to refer to the condition of
maximum population growth rate and not to any other parameters. The characteristics of the
population in terms of cell cycle time and population growth rate determined from the cycle time
are shown in Table 9 for the two mutation rates. These values are obtained from the simulation
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of the refined model using the model parameters found out from the insilico evolution for the
case of two mutation rates, at the time of convergence. The parameters used are shown in Table
9. The calculated population characteristics are in reasonable agreement with the values observed
for the yeast strains used in our research lab.

Figure 23: convergence of cell mass for mutation rates 0.2 (Left) and 0.4 (Right)
Table 10: Parameter values at the time of convergence for mutation rates, 0.4 and 0.2
Mutation Rate
Convergence considered after
Iteration k1
c2
k3
k4
J4
k5_1
k5_11
J5
k6_1
k6_11
J6
Nx
c7

0.2

0.4
2000
8.136948
3.92E-05
0.018778
1.305939
0.010195
0.366755
4.601016
1.511774
0.01643
23.40614
139.1396
5.041864
0.143474

3000
61.91434
8.61E-05
0.250774
3.538061
0.014855
0.143234
405.8477
0.182309
0.000514
60.04024
10.92971
2.016789
0.198089
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Table 11: Population characteristics calculated for the optimal parameters from insilico evolution
Mutation Rate
0.4
0.2

Population doubling
Population growth
time, min
rate, min-1
98.666
0.007025
97.6
0.0071

For both the mutation rates, similar trends are observed for the evolution of parameters of
cells in the system. Plots showing the variation of parameters in the insilico evolution for
mutation rate 0.2 are shown in Fig. 24, Fig. 25 and those for mutation rate 0.4 are shown in Fig.
26, Fig. 27. One typical behavior observed is that those parameters either increase or decrease
towards improved values as the cell mass approaches its convergence and then they start
fluctuating, remain constant or follow the same direction of increase or decrease with
intermittent fluctuations. Fig. 24 shows the results for parameters – k1, k3, k4, k5”, c7 and k6”
for a mutation rate of 0.2. For example, parameter k5” smoothly reaches a value close to 5 at the
time of convergence, and then fluctuates rarely falling below this value. It fluctuates by a factor
of 7 to reach 35. The range of these fluctuations indicates the sensitiveness of the parameter k5”
in the model. Parameter c7 also follows a similar behavior of reaching a value of 0.15 at the time
of convergence and then fluctuates around this value with a maximum factor of 2. Fluctuations
are observed in parameters k1, k3, k4 and k6”. However, the magnitude of deviations of the
values of these parameters from the values observed at convergence varies. It depends on the
sensitivity of the model to each parameter.
Fig. 25 shows some parameters which do not show many fluctuations. They either move
towards a final value asymptotically or stay constant. Parameter Nx remains constant at the
starting value of 5 with minor fluctuations. Parameters c2, k5‟ and k6‟ approach values close to
zero.
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Figure 24: Parameters in insilico evolution for mutation rate, 0.2. There are small fluctuations in
these parameters till the point of convergence, fluctuations of different magnitude are observed
afterwards. Insilico evolution serves as a measure of sensitiveness of the model to these
parameters.
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Figure 25: Parameters of the insilico evolution for mutation rate, 0.2. Parameter Nx, fluctuates
slightly around 5, J5 is increasing with fluctuations. Other parameters show asymptotic behavior.
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The insilico evolution results for mutation rate 0.4 are shown in Fig. 26, Fig. 27.
Parameter k1 reaches a value close to 50 at the time of convergence, and then fluctuates rarely
falling below this value of 50. It changes by a factor of 7 to reach 350. Parameter k3 also follows
a similar behavior of reaching a value of 0.1 at the time of convergence and then starts
fluctuating up to a factor of 7. Parameter k5” also reaches a value at the time of convergence and
undergoes fluctuations of several orders of magnitude in line with the fluctuations observed for
parameters k1 and k3. Similar trend is observed for parameter c7.
Results for parameters J6, Nx, k6”, c2, J5 are shown in Fig. 27. Parameter J6 reached
convergence in the case of high mutation rate of 0.4 whereas it fluctuated for low mutation rate
of 0.2. Nx remains constant for the case of high mutation rate also, however, it attains a different
constant value of 2 compared to a value of 5 observed for low mutation rate. Similarly,
parameter k4 does have fluctuations of small magnitude despite large fluctuations in parameters
k1, k3, c7, k5”. Parameters like J6, Nx, k4 whose values stay in a close range in the insilico
evolution seem to be important for the parameter estimation problem because their possible
values for a given growth rate are in small range. Thus, insilico evolution algorithm gives an idea
about the sensitivity of the model to different parameters.
Effect of mutation rate
Many nonlinear optimization search algorithms, when they are far away from optimal
solution use large magnitudes of perturbations in the optimization variables and the perturbations
become small when near the optimum. It is a point of investigation to see how mutation rate
which is an indication of perturbation made to the parameters, changes with the distance from the
optimal solution. It is mentioned in the earlier discussion about the parameters that show
considerable magnitude of fluctuations after reaching convergence in mass (all the cells in the
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Figure 26: Parameters in insilico evolution for mutation rate,0.4. Parameter k5” fluctuates to
several orders of magnitude, while k1, k3, c7 fluctuate to a factor of 7. Model appears sensitive
to fluctuations in parameter k4.
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Figure 27: Insilico evolution of parameters for mutation rate, 0.4. Parameters J6, Nx reached
convergence. The other parameters stay close to zero due to large fluctuations in parameters k5”,
k1, k3 at this mutation rate.
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system have reached their maximum possible growth rates), will not show much fluctuations
before reaching the convergence. They moved in a smooth manner towards the optimal solution
where cells grow at a maximum rate, only then started fluctuating to considerable magnitude
without causing any cell deaths. At low growth conditions, where the parameters are far away
from the optimal solution, the perturbations in the parameters should be very small. Hence, for
the present initial parameters, it appears that we should start with small mutation rate. The results
of the insilico evolution simulations performed for large mutation rates confirm this point. All
the cells have died after a few iterations of the insilico evolution for very high mutation rates.
After reaching the optimal solution, the magnitude of fluctuations is large for higher
mutation rates than for small mutation rate. For example, parameter k5” fluctuates to several
orders of magnitude for mutation rate of 0.4 compared to fluctuations in other parameters k1, k3,
c7 which change by a factor of 7. This shows that the parameter k5” may not be that important in
fitting the model to steady state distributions using least square technique. However, for the
mutation rate of 0.2, the magnitude of fluctuations of k5” is comparable to the fluctuations in the
values of parameters k1, k3, c7. This makes it equally important in the model fitting even though
it is shown to be less important from the high mutation rate observation. Thus, using higher
mutation rates after reaching the optimal solution helps in identifying sensitivity of parameters.
The time to reach convergence and also execution time of the algorithm may change with
mutation rate. The algorithm is executed for mutation rate of 0.6 and the result of convergence of
cell mass is shown in Fig. 28. It has reached the lowest value of cell mass, which is the optimum,
in less than 2000 iterations, but do not appear to be converged as it continues fluctuating. Also,
the average cell mass for the population is slightly higher than that observed for lower mutation
rates of 0.4 and 0.2. The results of execution time for each of the mutation rates are shown in
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Table 5. It took less time for the execution of algorithm to 10000 iterations for low rate of 0.2.
Even though the execution time for the rate 0.6 is less than that for the rate 0.4, the doubling time
of cells is high which gives a less population growth. Thus, mutation rate is an important factor
to be investigated to accomplish many improvements to the insilico evolution algorithm
proposed here, when applied for more complex models.

Figure 28: Convergence of cell mass for mutation rate of 0.6
Table 12: Execution time and average cell mass for different mutation rates
Mutation Rate
Total Execution Time, min
Average time for iteration,
milli sec
Doubling time, min
Average mass, pg

0.2
65

0.4
248

0.6
208

396
83.5
0.856

1490
87.13
0.9168

1247
97.1
1.04

5.4.2 Summary
Using insilico evolution algorithm, optimal parameters are obtained that gave the
population doubling time in reasonable agreement with the experimental value. These parameters
can be selected as an initial estimate of the model parameters. Cell mass converges towards a
minimum value and parameters either tend towards a lower value or higher value at the point of
convergence. When iterations are continued even after the convergence of mass, fluctuations of
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small to large range in the parameters are observed. The extent of fluctuations gives an idea
about the sensitivity of the model to these parameters when the selection rate is keeping up with
the mutation rate. If the mutation rate is fast enough that there is no improvement in the
population composition, then all the perturbations in the parameters are random variations and
we cannot draw many conclusions from that without investigating further on mutation rate.
Large fluctuations of the parameters mean that the parameter will have less influence on the
dynamics of the population. Mutation rates affect the speed of achieving the solution and these
are to be intelligently adjusted to get to the final solution minimizing the fluctuations.
5.5. Conclusions
The basic cell cycle model is modified to include the features observed for experiments
of budding yeast. Mother cells are assumed to acquire a constant cell mass known as critical cell
mass and daughter cells will have large variations in their mass at the time of birth. Simulations
are performed by including the feature of critical cell mass in the cell cycle model and the shape
of mass distributions obtained for specific growth rates of large range give reasonable result.
Further direction from the insilico evolution simulations is to use a least square fit of
distributions of states of key components of cell cycle oscillator those are obtained from flow
cytometry. There are least square techniques available in the literature to fit DNA distributions
to the models (Dean and Jett, 1974; Johnston D. A., 1978; Bailey, 1981). However, even a
moderately realistic cell cycle model will have many parameters some of which may not be
having great impact on the goodness of the fit of the distributions. The parameters of importance
for the fitting problem can be identified from the insilico evolution simulations by the range over
which they fluctuate. In addition to the insilico evolution simulations which give an idea about
the sensitivity of the model to various parameters, sensitivity analysis of the parameter set can be
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carried out using other methods (Gunawan et al., 2005) to identify the important model
parameters.
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CHAPTER 6. CONCLUSIONS AND FUTURE DIRECTIONS
A stochastic model developed based on a cell cycle model that is representative of a
simple eukaryotic system is described. The kinetics of biochemical interactions among the
species involved in the chosen cell cycle network are described by stochastic formulation and
stochastic simulation algorithm is used to simulate the time course trajectories of the state of the
system. Using a Monte Carlo strategy, a large number of independent simulations of the system
with the same initial state will give different realizations of the state and thus give a distribution
of states. All the cells in the same initial state will attain different states in time and thus the
model depicts the loss of cell synchrony and the population heterogeneity in terms of their states
is predicted from the stochastic model based on single cell kinetics. Thus, the stochastic cell
cycle model presents Monte Carlo solution to the population balance equations.
Model‟s ability to predict the population growth and to represent the heterogeneity of
population is used in developing an integrated chemotherapic model that combines the growth of
cells described by cell cycle model with simple pharmacokinetics describing the decay of drug in
the body and pharmacodynamics describing the killing effect. Killing effect of a cancer drug on
healthy cells and cancer cells will be different and selection of a type of drug injection in terms
of various dose-frequency combinations to maximize the killing on cancer cells and minimizing
the effect on healthy cells are tested using the basic cell cycle model with different parameters
for each type of cells. Such a methodology has great scope in predicting the outcome of a drug
treatment and drug administration protocol on a heterogeneous patient population and thus to
assist in insilico screening of cancer drugs and testing clinical trial protocols.
Budding yeast is a model organism frequently studied for cell cycle research and the
basic cell cycle model is refined in a systematic way to make it more realistic representation of
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the budding yeast. The mass distributions predicted from the model are in qualitative agreement
with the experimental observations. At high growth conditions, the mass distribution contains a
double peak and it becomes unimodal at very low growth conditions which is predicted by the
model. The qualitative agreement is not sufficient to use it in making predictions about the
behavior of organism and thus a systematic methodology is developed in a direction to make the
model accurate in quantitative aspects as well. Plausible values of the model parameters with
proper units are assigned by making comparisons between the average mass and doubling time
of the population of cells with the predictions obtained from model parameters with arbitrary
units. Insilico evolution, an optimization strategy, is used to predicting the evolution of model
parameters through generations of mutation and selection towards the parameter values that
correspond to maximum growth rate of the population. There are many combinations of the
model parameters that are selected by the evolution algorithms as to give maximum growth rate.
Insilico evolution simulations show fluctuations to several orders of magnitude for some
parameters, fluctuations in a close range for some indicating different sensitivities of the model
parameters. The exact set of parameters can be obtained by using nonlinear least squares
techniques to fit the distribution of important proteins in the biochemical network obtained from
the model to the measured distributions. Insilico evolution, however, serves to identify the
important parameters in terms of goodness of fit to the distributions, which only can be used for
model fitting problem. From the computational aspects, further investigation of effect of
mutation rate on improving the speed of selection, optimal solution.
A methodology presented for budding yeast with small set of compounds and reactions
can be extended to more complex networks containing large number of reactions. Presently,
work is going on to extend the learning gained through the experience of formulating stochastic
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model for a simple eukaryotic system of biochemical network to more realistic networks of
budding yeast cell cycle containing 10 components and 42 components respectively. The
challenges lie ahead in handling more diverse set of reaction kinetics concepts such as quasi
steady state assumption, partial equilibrium, and stiffness in the reaction set for which
implementation of approximation algorithms is to be investigated. The original exact stochastic
simulation algorithm (SSA) of Gillespie (1976, 1992) will perform satisfactorily for small
systems and will be computationally demanding when it has to deal with large set of reactions as
discussed in a study (Kierzek, 2002). Approximate algorithms discussed in the chapter 2 of this
report are developed to speed up the simulations. Combining these approximations with parallel
computing power of clusters of computers and multiprocessors should make the computational
requirements less demanding and this is another direction for future work. Another task is to
improve the features of insilico evolution strategy. At present, a single mutation rate is used to
obtain the optimum solution starting from an initial set of parameters. Based on the discussion in
the previous chapter, mutation rate might influence the speed of convergence of the optimization
problem and also it may lead to different optimal solutions.
Developing stochastic models with more realistic features and combining them with the
advanced computing technologies will help us in realizing many applications of those models in
the fields of biology and medicine and thus for the better serving of the mankind.
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APPENDIX A. DOCUMENTATION FOR THE INSILICO EVOLUTION PROGRAM IN
VB.NET
A.1. Overview
Insilico evolution is a type of evolutionary optimization method that we employed for
selecting the best parameter set for the stochastic cell cycle model, that give maximum
population growth rate of cells. Like other optimization search algorithms, the execution of
algorithm requires an initial guess of the optimization variables. Here, the optimization variables
are the parameters of the cell cycle model. The working principle of the algorithm and the cell
cycle model on which the insilico evolution program is built is described in chapter 5 of this
report. Here, the procedure for the execution of the user interface developed in VB.Net platform
is explained for convenience of the users of this program.
Various windows in the user interface are explained below.
A.2. Main Window

Figure A1: Main Window for Insilico Evolution code
As is shown in the window, it asks for the seed to start the random number generator in
the program. Entering a negative number, the program will generate the seed according to the
timer in the system. User can give any value for the seed. Clicking on the “Exit” tab, terminates
the program.
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A.3. Model Parameters

Figure A2: Opening window after clicking on “Model Parameters” tab.
Clicking on the “Model Parameters”, the main window will like above. There are five
different sub menus appear.
A.4. Model Parameters - Cell Cycle Reactions
Clicking on the “Cell Cycle Reactions” will open a new window as shown below.

Figure A3: Opening window after clicking on “Cell Cycle Reactions” in “Model Parameters” tab
of main window.
The window is self-explanatory. These are the initial cell cycle parameters for all the
cells existing at the start of the insilico evolution algorithm. It has tabs “Load Parameters” and

108

“Save Parameters” clicking on which the program asks for the file name to load or save the
model parameters respectively.
Clicking on “Done” will close the window.
A.5. Model Parameters – Trigger Values
Clicking on the “Trigger Values” will open a new window as shown below.

Figure A4: Opening window after clicking on “Trigger Values” in “Model Parameters” tab of
main window.
As written on the window, it asks for entering the trigger values for the start, division and
cell death events.
Clicking on “Done” will close the window.
A.6. Model Parameters – Division
Clicking on the “Division” will open a new window as shown below.
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Figure A5: Opening window after clicking on “Division” in “Model Parameters” tab of main
window.


Minimum Cell Mass is the minimum biologically possible value of cell mass for
budding yeast.



is the maximum deviation allowed from the value of critical cell mass that is assigned
to the mother cell after division.



Constant Mother Mass is the value of the critical cell mass. In the model, start event
occurs only when cell mass crosses this threshold.

Clicking on “Done” will close the window.
A.7. Model Parameters – Single Cell Growth
Clicking on the “Single Cell Growth” will open a new window as shown below.


Clicking on the button “First Order Single Cell Kinetics” will ask for specific growth
rate, with units as time-1



Clicking on the button “Zero Order Single Cell Kinetics” will ask for growth rate for zero
order kinetics. The units here should be in “mass/time”
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Figure A6: Opening window after clicking on “Single Cell Growth” in “Model Parameters” tab
of main window.
Clicking on “Done” will close the window.
A.8. Model Parameters – Mutation Rates
Clicking on the “Mutation Rates” will open a new window as shown below.

Figure A7: Opening window after clicking on “Mutation Rates” in “Model Parameters” tab of
main window.


Mutation Range is the range by which the model parameter can be perturbed from the
existing value. Mutation range should have a mean value equal to one.

Clicking on the “Mutation Rates” will open a new window as shown below.
A.9. Main Window – Enter Seed Value for Random Number Generator
After completing all the inputs in the Model Parameter, click on “Done” in the main
window to proceed further.
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Figure A8: The Main Window, shown again to proceed further after completing the inputs.
After entering the “seed” value for the random number generator, click on “Done” and
the main window appears as shown below.
A.10. Main Window – Enter Inoculum Size

Figure A9: Opening window when clicked on “Done” after entering the “seed” value.


User should enter “Inoculum Size” which by default uses a value of 100 in the algorithm.
This is the number of cells to start with in the insilico evolution algorithm.

After clicking on “Enter Inoculum Size”, the main window looks like below.
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A.11. Main Window – Load Inoculum File

Figure A10: Main Window after clicking on “Enter Inoculum Size”.
After entering the size of the inoculum, user needs to select the file from which the initial
cells should be selected. This file is called inoculum file in our model terminology.


Inoculum File – This is the file where states of a large set of new born cells are stored.
State of the cell is in terms of the mass, and number of molecules of each of the four
components and the status of the cell in terms of start event occurred or not. Since all
these cells are newly born, the „start event‟ is stored as FALSE, a Boolean variable.

A.12. Main Window – Save Parameter Values after Each Iteration

Figure A11: New Window after finishing entering the inoculum file
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After supplying the program with the „inoculum file‟ and clicking OK, a new window
opens as shown above. It will ask for the user if the parameters after each iteration of the insilico
evolution simulations should be saved.
These parameters are the average of each of the parameters for the 100 cells in the system
after eliminating some of the cells randomly.
If clicked „yes‟, user need to specify the file name in which the parameters will be stored
and proceeds to the next step.
If clicked „no‟, the program proceeds to next step.
A.13. Main Window – Save Final Distribution
User will be asked then if the final distribution of states should be saved. The window is
as shown below.

Figure A12: New Window opens after clicking on „yes‟ or „no‟ to the save parameters window.


Final Distribution of States – This is the distribution of the states of the 100 cells
existing in the system after each iteration. By default, program stores the states of five of
the 100 cells. It can be changed in the program.
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A.14. Main Window – Start
After responding „yes‟ or „no‟ for saving the final distribution, the Main Window will
look like this.

Figure A13: Main Window after clicking „yes‟ or „no‟ on the save final distribution window.
At this stage, all the inputs to the program are given and the program is ready to start
executing.
Clicking on the “Start” button, Main Window appears as shown below.

Figure A14: Main Window while the program is being executed.
The value in the box for “Iteration No” is the number of iterations of insilico evolution
program execution that have been completed.
A.15. Data Files
The results of the insilico evolution simulation are stored in two files. One is the file for
storing the average model parameters, cell mass and doubling time of the cells existing after each
iteration and execution time of the iteration. It also contains the input values supplied to the
program at the beginning of the simulation. The file appears as shown below.
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Figure A15: Output file in which parameters at the end of each iteration are shown
Another output file is for saving the final states of a selected number of cells after each
iteration. This will be helpful if we need to check how the states of the cells change as the
parameters are changed. The output file for the final distribution of states is shown next.
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Figure A16: Output file for saving the final distribution of states of cells existing in the system
after each iteration.
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APPENDIX B. IDENTIFICATION OF TARGET REACTIONS FOR CHEMOTHERAPY
MODEL
B.1. Identifying the Target Reactions for Chemotherapic Drug
Simulation results of the time course of population growth of normal cells and target cells
for continuous inhibition of each of the seven reactions for wide ranging inhibition factors are
obtained to identify good target reactions. In Figure B1, natural logarithm of number of live cells
(Nc) is plotted with time for the two cyclin degradation reactions (reactions 2, 3). The population
of the target cells has increased as a result of inhibition and thus these two reactions are
eliminated as the target reactions for drug.

(a)

(b)

Figure B1: inhibitory effect of reaction 2 (a) and reaction 3 (b) on target cell population growth
The corresponding results for the other reactions are shown in Figure B2 expressed in
terms of the time course of the fraction of total live cells in normal and target populations at
different inhibition levels (denoted by different inhibition factors). An ideal drug target reaction
should have the value of the live cell fraction approaching zero for target cells and one for the
normal cells after inhibition. However, from Figure B2(a), it appears that both types of cells are
equally affected by inhibiting the cyclin synthesis reaction (reaction 1). For low inhibition
factors, only a small reduction in the fraction of target cells is obtained and at higher inhibition
more number of cells are killed and the fraction moves close to zero. But, the same trend is
obtained for normal cells as well. In Figure B2(a), for the same dosage (or inhibition factor), live
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cell fraction of healthy cells is less than that of the target cells.. For example, at 0.333 dosage (k1
= 500 slow) healthy cells fraction is close to 0.6, whereas at 0.31 dosage, fraction of the target
population is close to 0.6 (between doses 0.31 and 0.35). Hence, the inhibition effect is acting
almost equally on normal and target cells which reveals that targeting reaction 1 is suitable for
reducing tumor burden but not recommended from the toxicity considerations Periodic injection
of the drug that facilitates the normal cells to recover from the slow growth because of the
inhibition may help the treatment to be effective. On the basis of continuous inhibition, reaction
1 may not be suitable target for the present target cells.
APC inactivation (Reaction 4) (Figure B2(b)) appears to be a target reaction for a
chemotherapic drug. For normal population, at 0.2 dosage (k1 = 160), the fraction is close to 0.7
and will increase for higher doses. At nearly the same dosage (0.232), the fraction of target cells
is very less.

(a)
Figure B2: inhibitory effect of reactions 1,4,5,6,7 (a,b,c,d,e respectively) on population growth
of target cells (left side) and normal cells (right side). In the labels in figures, fast denotes target
cells and slow denotes normal cells.
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(Figure B2 continued)

(b)

(c)

(d)

(e)
For continuous inhibition the inhibition factor (or dosage) can be varied between 0.2 –
0.325 without causing toxicity to the normal cells. For this dosage range, live cell fraction of the
normal cells varies from 0.7 to 0.825 and for target cells it is 0.1 to 0.7. These simulation results
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are identical to the dose escalation studies conducted in clinical trials to establish safe dose limits
for chemotherapic drug administration strategies
APC activation (reaction 5) (Figure B2(c)) is not a target reaction as it appears as
equivalently toxic to both target cells and normal cells. At 0.725 dosage, the toxicity of the drug
targeting reaction 5 is more dominant than its effectiveness in killing the target cells. A similar
observation can be made for reaction 6 (activator protein synthesis) (Figure B2(d)). Hence, both
these reactions fail to be good targets when acted alone on body of cells containing both normal
and target cells.
Reaction 7 (activator protein degradation) (Figure B2(e)) is a possible target reaction. At
the dosage 0.25, the fraction of healthy cells is around 0.8. For higher doses, this fraction is
slightly above 1 which is an indication of reduced cell cycle length of normal cells. For target
cells, for 0.75 dosage, the target cell fraction is very less and if the dosage is increased up to 0.5,
almost all the cells will die. The large negative slope of the time course plot of target cells while
the slope for normal cells is close to zero indicates that continuous action of the drug at specific
dosages will contribute to the high rate of killing of target cells without affecting normal cells.
Since the fraction of healthy cells is close to 0.8 even at 0.25 dosage, the range of drug dosage
for continuous inhibition of reaction 7 can be selected as 0.25 – 0.8 (for this dosage, live cell
fraction for normal cells is 0.8 - 1.1; for target cells is 0 - 0.2)
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APPENDIX C. FORTY THREE COMPONENT MODEL
C.1. Description of the Model and Molecular Mechanism
Stochastic cell cycle model is developed based on the deterministic model presented in
(Chen et al., 2004). A brief description of the molecular mechanism proposed in the
deterministic version is described here. A single cyclin-dependent kinase (Cdk), cdc28
combining with two families of cyclins, Cln1-3 and Clb1-6 controls the major cell cycle events
in the budding yeast. It is approximated that cdc28 is present abundantly and rapidly combines
with cyclins as soon as they are synthesized. Cln1-2 play major role in bud formation and their
concentration peaks in late G1 phase. Cln3 governs the size of the cell and the initiation of Start
event (license to start DNA synthesis). Clb5-6 are responsible for initiating DNA replication
whereas Clb3-4 assist in the replication process. At least one of Clb1-Clb2 pair is necessary for
completing mitosis. In the model some of these cyclins are lumped together and represented as a
single cyclin. Cln2 represents Cln1-2, Clb2 represents Clb1-2, Clb5 represents Clb4-5. Clb3-4
are not included in the model as they are considered to be assisting the activities of other cyclins.
Most of the earlier part of the G1 phase is abundant in proteins (Cdh1, Sic1 and Cdc6)
whose role is to keep S/G2/M phase cyclins, Clb5 and Clb2 in low concentrations. Cdh1/APC
degrades the cyclins whereas Sic1 and Cdc6 together referred to as cyclin-dependent kinase
inhibitors (CKIs), inhibit the activity of cyclins. Cell grows to a critical size in G1 phase to have
enough Cln3 and Bck2 that activate the transcription factors SBF and MBF for synthesizing Cln2
and Clb5. Cln2 and Cln3 are not inhibited by Cdh1 and CKI activities. When the abundance of
Cln2 reaches sufficient level, it inhibits the activities of Cdh1 and CKIs leading to the synthesis
of Clb5. Clb5 and Cln2 together shut off the activities of CKI and Cdh1 and this will allow the
synthesis of Clb2 which activates its own transcription factor Mcm1. DNA synthesis is initiated
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after Clb5 and Clb2 are reached to sufficient levels. After the cell enters S-phase, synthesis
activities of Cln2, Cln3 and Clb5 are turned off and Clb2 drives the cell into mitosis. Clb2
phosphorylates the components of anaphase promoting complex (APC) and stimulates the
synthesis of Cdc20 which is crucial for the cell‟s exit from mitosis in combination with mitotic
exit network (MEN) pathway.
MEN pathway contains proteins Lte1, Bub2, Tem1, Cdc15 and Cdc14 with the ultimate
result of releasing Cdc14 in active form from RENT complex. Cdc14 is required for the exit of
mitosis. Cdc14 plays role in the activation of CKIs, Cdh1 and inactivation of Cdks. Cdc15 is the
end point of the MEN pathway and is responsible for the release of Cdc14. Cdc15 is activated by
Tem1. Bub2 is a checkpoint protein which prevents the exit from mitosis if there are defects in
the mitotic spindle pole formation. Lte1 is involved in the activation of Tem1.
APC/cdc20 becomes active when Mad2-dependent checkpoint signal is released after the
chromosomes are aligned properly and it initiates the exit from mitosis. First, it degrades Pds1
releasing Esp1 prompting the sister chromatid separation. Active Cdc20 promotes degradation of
phosphatase PPX that keeps Net1 in its active unphosphorylated form which holds on to Cdc14
forming RENT complex. When PPX is degraded, Net1 gets phosphorylated by Cdc15 releasing
Cdc14 which acts against Cdks in the activation of Cdh1 (degrades cyclin Clb1-2) and Swi5
(transcription factor for Cdk-inhibitor Sic1) and returns the cell to G1 phase.
C.2. List of Biochemical Reactions Representing the Cell Cycle Network
The set of biochemical reactions and corresponding reaction propensities and reactant
combinations are listed in the Table B2. Different species involved in the model are listed in
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Table B3. These are derived from the deterministic model of (Chen et al., 2004). However,
modifications are made in the formulation of some of the reactions and reaction propensities.
Production of both Cln3 and Bck2 are taken as continuous variables and proportional to
the cell mass in the deterministic model.

;

In the stochastic formulation, these expressions are included as reaction propensities for
synthesis reactions of Cln3 and Bck2 respectively.
Table B1: some differences in the reaction kinetic expressions between the deterministic and
stochastic versions of the budding yeast cell cycle model
No.

Reaction

3.

Cln3 synthesis

Reaction Propensity

No. of reactant
combinations
1

4.

Bck2 synthesis
1


Cdh1, Net1, Swi5, is synthesized in active form, but degraded in both active and inactive
forms.



Cdc14 is synthesized in active form and degraded in inactive form.



Cdc20 is synthesized in inactive form.



The rate expressions for activating [SBF], [MBF],[Mcm1] contain Goldbeter functions
that act as switches in the deterministic model. Mechaeli‟s Menten formulae are used in
the stochastic model to make the implementation of switch type activity easier.
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Table B2: List of Reactions used in the stochastic model
No.

Reaction

1.

Cln2 degradation

Reaction
Propensity, Cn

No. of
Reactant
Combinations,
hn
[Cln2]

2.

Cln2 synthesis
1

3.

Cln3 synthesis
1

4.

Bck2 synthesis

5.

Clb5 synthesis

1
1
6.

Clb5 degradation

7.

Inhibition of Clb5 by Sic1

[Clb5]
[Sic1][Clb5]
8.

Inhibition of Clb5 by Cdc6

9.

Clb2 synthesis

[Cdc6][Clb5]
1
10.

Clb2 degradation
[Clb2]

11.

Inhibition of Clb2 by Sic1
[Clb2][Sic1]

12.

Inhibition of Clb2 by Cdc6
[Clb2][cdc6]

13.

Activation of promoting factor SBF
[SBF]i

14.

Inactivation of promoting factor SBF
[SBF]a

15.

Activation of promoting factor Mcm1
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[Mcm1]i
16.

Inactivation of promoting factor
Mcm1
[Mcm1]a

17.

Swi5 synthesis
1

18.

Degradation of active Swi5
[Swi5]a

19.

Inactivation of CKI promoting factor
Swi5
[Swi5]a

20.

Degradation of inactive Swi5

21.

Activation of CKI promoting factor
Swi5

[Swi5]i

[Swi5]i
22.

Sic1 synthesis
1

23.

Cdc6 synthesis
1

24.

Phosphorylation of Sic1
[Sic1]

1, 2 2+ 1, 2
5+ 1, 2
2
25.

2+ 1, 5

Dephosphorylation of Sic1P
[Sic1P]

26.

Degradation of Phosporylated Sic1
[Sic1P]

27.

Dissociation of inactive trimer C2 to
Clb2, Sic1
[C2]

28.

Degradation of Clb2 in inactive
trimer C2
[C2]

29.

Phosphorylation of Sic1 in trimer C2
[C2]

30.

Dephosphorylation of Sic1P in trimer
C2P
[C2P]

31.

Degradation of Sic1P in trimer C2P
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[C2P]
32.

Clb2 degradation in trimer C2P

33.

Dissociation of inactive trimer C5 to
Clb5, Sic1

[C2P]

[C5]
34.

Degradation of Clb5 in inactive
trimer C5
[C5]

35.

Phosphorylation of Sic1 in trimer C5
[C5]

36.

Dephosphorylation of Sic1P in trimer
C5P
[C5P]

37.

Degradation of Sic1P in trimer C5P
[C5P]

38.

Clb5 degradation in trimer C5P
[C5P]

39.

Phosphorylation of Cdc6
[Cdc6]

6, 2 2+ 6, 2
5+ 6, 2
2
40.

2+ 6, 5

Dephosphorylation of Cdc6P
[Cdc6P]

41.

Degradation of Phosporylated Cdc6
[Cdc6P]

42.

Dissociation of inactive trimer F2 to
Clb2, Cdc6
[F2]

43.

Degradation of Clb2 in inactive
trimer F2
[F2]

44.

Phosphorylation of Cdc6 in trimer F2

45.

Dephosphorylation of Cdc6P in
trimer F2P

[F2]

[F2P]
46.

Degradation of Cdc6P in trimer F2P
[F2P]

47.

Clb2 degradation in trimer F2P
[F2P]
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48.

Dissociation of inactive trimer F5 to
Clb5, Cdc6
[F5]

49.

Degradation of Clb5 in inactive
trimer F5
[F5]

50.

Phosphorylation of Cdc6 in trimer F5

51.

Dephosphorylation of Cdc6P in
trimer F5P

[F5]

[F5P]
52.

Degradation of Cdc6P in trimer F5P
[F5P]

53.

Clb5 degradation in trimer F5P

54.

Inactivation of hypothetical protein
IE (may be the phosphorylated form
of APC)

[F5P]

[IEP]a
55.

Activation of hypothetical protein IE
[IEP]i

56.

Synthesis of Cdc20 (in inactive form)
1

57.

Degradation of inactive-Cdc20

58.

Activation of Cdc20

[Cdc20]i
[Cdc20]i
59.

Inactivation of Cdc20
[Cdc20]a

60.

Degradation of active-Cdc20

61.

Synthesis of Cdh1 (in active form)

[Cdc20]a
1
62.

Degradation of active-Cdh1
[Cdh1]a

63.

Inactivation of Cdh1
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[Cdh1]a

64.

Activation of Cdh1
[Cdh1]i

65.

Degradation of inactive-Cdh1
[Cdh1]i

66.

Inactivation of Tem1
[Tem1]a

67.

Activation of Tem1
[Tem1]i

68.

Activation of Cdc15
[Cdc15]i

69.

Inactivation of Cdc15
[Cdc15]a

70.

Synthesis of Cdc14 (in active form)
1

71.

Degradation of active-Cdc14
[Cdc14]a

72.

Formation of RENT complex
[Net1][Cdc14]
a

73.

Formation of RENTP complex
[Net1P][Cdc14
]a

74.

Net1 synthesis
1

75.

Net1 degradation
[Net1]

76.

Phosphorylation of Net1
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[Net1]
77.

Dephosphorylation of Net1P
[Net1P]

78.

Degradation of Net1P
[Net1P]

79.

Degradation of Net1 in RENT
complex

80.

Degradation of Net1P in RENTP
complex

[RENT]

[RENTP]
81.

Dissociation of RENT complex

82.

Dissociation of RENTP complex

[RENT]
[RENTP]
83.

Degradation of Cdc14 in RENT
complex
[RENT]

84.

Degradation of Cdc14 in RENTP
complex
[RENTP]

85.

Dephosphorylation of Net1P in
RENTP complex
[RENTP]

86.

phosphorylation of Net1 in RENT
complex
[RENT]

87.

PPX synthesis
1

88.

PPX degradation
[PPX]

89.

Pds1 synthesis
1

90.

Association of Pds1 and Esp1 to form
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PE
[Pds1][Esp1]
91.

Dissociation of PE to Pds1 and Esp1
[PE]

92.

Degradation of Pds1 in PE
[PE]

93.

Pds1 degradation
[Pds1]

Table B3: List of variables in the model
Variable
N(1)
N(2)
N(3)
N(4)
N(5)
N(6)
N(7)
N(8)
N(9)
N(10)
N(11)
N(12)
N(13)
N(14)
N(15)
N(16)
N(17)
N(18)
N(19)
N(20)
N(21)
N(22)
N(23)
N(24)

Symbol
Cln2
Cln3
Bck2
Clb5
Sic1
C5
Cdc6
F5
Clb2
C2
F2
(SBF)i
(SBF)a
(Mcm1)i
(Mcm1)a
(Swi5)a
(Swi5)i
Sic1P
C2P
C5P
Cdc6P
F2P
F5P
(IEP)i

N(25)

(IEP)a

N(26)

(Cdc20)a

N(27)
N(28)

(Cdc20)i
(Cdh1)a

Species
Cyclin involved in budding
Cyclin initiating start event
Protein initiating start event
Cyclin appearing in the late G1, involved in the synthesis of DNA
Stoichiometric inhibitor of Clb2, Clb5
Trimer of Clb5/Cdk and Sic1
Stoichiometric inhibitor of Clb2, Clb5
Trimer of Clb5/Cdk and Cdc6
Cyclin essential for exit from mitosis, present in S/G2/M phase
Trimer of Clb2/Cdk and Sic1
Trimer of Clb2/Cdk and Cdc6
Transcription factor for Cln2, in inactive form
Transcription factor for Cln2, in active form
Transcription factor for Clb2, Cdc20, Swi5 in inactive form
Transcription factor for Clb2, Cdc20, Swi5 in active form
Transcription factor for Sic1 and Cdc6, in active form
Transcription factor for Sic1 and Cdc6, in inactive form
Phosphorylated form of Sic1
Trimer of Clb2/Cdk and Sic1P
Trimer of Clb5/Cdk and Sic1P
Phosphorylated form of Cdc6
Trimer of Clb2/Cdk and Cdc6P
Trimer of Clb5/Cdk and Cdc6P
Intermediary enzyme, a hypothetical protein involved in activating
Cdc20, in inactive form
Intermediary enzyme, a hypothetical protein involved in activating
Cdc20, in active form
Activator of the APC; protein involved in Clb2, Clb5 and Pds1
proteolysis, and required for exit from mitosis, in active form
Inactive form of Cdc20
Activator of the APC; protein involved in Clb2 and Pds1 proteolysis,
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N(29)
N(30)
N(31)
N(32)

(Cdh1)i
(Tem1)a
(Tem1)i
(Cdc15)a

N(33)
N(34)
N(35)
N(36)
N(37)
N(38)
N(39)

(Cdc15)i
(Cdc14)a
Net1
Net1P
RENT
RENTP
PPX

N(40)

Pds1

N(41)
N(42)
N(43)

Esp1
PE
Cell Mass

active form
Inactive form of Cdh1
Protein activating Cdc15 in MEN pathway, in active form
Inactive form of Tem1
Component of MEN pathway, essential for releasing Cdc14, in
active form
Inactive form of Cdc15
Phosphatase required for exit from mitosis, exists in active form
Stoichiometric inhibitor of Cdc14
Phosphorylated form of Net1
Complex formed from Net1 and Cdc14
Complex formed from Net1P and Cdc14
Phosphatase keeping Net1 in unphosphorylated form that binds to
Cdc14
Stoichiometric inhibitor of Esp1 that prevents sister chromatid
separation
Protein required for sister chromatid separation
Complex formed from binding of Pds1 to Esp1
Continuous variable, mass of cell

The current model is described by 93 reactions consisting of 121 parameters, 43 state
variables including cell mass, as shown in Tables B2 &B3. Cell progresses through various
phases of cell cycle as the trigger values are satisfied.
For the cell to progress through the cell cycle, following events should occur in the order.
Each event is described with the corresponding trigger variable in the parenthesis.
1. Origin re-licensing (when Clb2+Clb5 drops below threshold) – cell will be ready for next
round of replication
2. Origin activation (when Clb2+Clb5 subsequently raises above threshold) – DNA
synthesis will start
3. Entry into mitosis when spindle is aligned (when Clb2 rises above threshold)
4. Esp1 activation (when Esp1 rises above threshold, after Pds1 is degraded) – cell is ready
for division and waits for the Clb2 level to drop down below a threshold value
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5. Nuclear division (when Clb2 drops below a threshold) – cell division occurs
Another condition that is included in the model is the provision for cell death occurrence.
When the cell mass increases above a threshold value, cell is considered dead.
C.3. Modules for the VB code

Figure C1: VB form for supplying the Initial Conditions and Trigger Values
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Figure C2: Visual Basic form for Main Window

Figure C3: Visual Basic form for supplying the output parameters

134

135

Figure C4: Visual Basic form for supplying the Parameters for reactions
C.4. Approach for the Selection of Initial Conditions and Trigger Events
For the model to be executed, initial conditions and trigger values should be selected
properly along with the parameter values to give oscillations. Ghaemmaghami et al.
(Ghaemmaghami et al., 2003) and Cross et al. (Cross et al., 2002) have published the results of
their experiments on budding yeast cell cycle network. Their results contain average copies of
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different proteins (molecular concentrations) during the cell cycle of a haploid cell growing in
asynchronous culture.
Parameters used in the deterministic model of Chen et al. (Chen et al., 2004) do not have
units. Matlab codes for the deterministic model are obtained from Prof. Cross‟s research group.
Using the codes, it is possible to obtain plots for the expression of different proteins during the
cell cycle. With slight modifications to the code, average concentrations can be found out in a
given cell cycle. Molecular concentrations during different phases of the cell cycle can be
estimated by equating the dimensionless average concentrations to the average molecular
concentrations. It is proposed that a reasonable estimate of trigger values for the six different
transitions in the model can be obtained using this approach.
Assigning units to the parameters is discussed in Chen et al. (Chen et al., 2004) which
might be helpful in giving the initial guess of the parameters.
C.5. Trigger events in the VB code
In the deterministic version of the model, three rate constants kbub2, klte1, kmad2 are
designed to have two different values, a higher and a lower value depending on which phase of
the cell cycle the cell is in. When there is spindle defect, protein Bub2 will inactivate Tem1 in
MEN pathway. Protein Lte1 will try to activate Tem1. Also, when the kinetochores are
unattached, Mad2 dependent checkpoint signal will inactivate Cdc20.


Replication
If Relicence And (N(3) + N(4)) > Replication_Trigger Then
Replication = True
Relicence = False
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k117 = kbub2_high
k63 = kmad2_high
End If
When the trigger for replication is satisfied, kbub2 and kmad2 are kept high to prevent the
activation of mitotic exit network.


Mitosis
If Replication And N(3) > Mitosis_Trigger Then
Mitosis = True
Replication = False
k117 = kbub2_low 'decreased kbub2
k63 = kmad2_low 'decreased kmad2
k118 = klte1_high 'increased klte1
End If
When the trigger for mitosis is satisfied, kbub2 and kmad2 are kept low and klte1 is kept high

to activate the mitosis exit network.


Division
If esp1 And N(3) < Division_Triger Then
Division = True
esp1 = False
k118 = klte1_low ' klte1 is decreased
After the division occurred, klte1 is again kept low to stop the mitotic exit network

activities.
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APPENDIX D. TEN COMPONENT MODEL
D.1. Description of the model
Based on the learning from building small model of four cell cycle components, using
stochastic formulation, the next step is to extend the understanding to build models that include
more details and components of the cell cycle reaction network. In that direction, the stochastic
formulation is extended to a cell cycle model containing ten components with many interactions
among them. It is developed earlier by Hjortso (unpublished work) based on a deterministic
model of Tyson and Novak (Tyson, 2000) and is presented here along with the modifications on
the original stochastic model.
A schematic of the cell cycle reaction network which is redrawn based on the model of
Tyson and Novak (Tyson, 2000) is shown in Fig. D1.
Various features of the cell cycle model are described as followed. Early in the G1 phase,
the S-G2-M cyclin, CycB is low because it is rapidly degraded in the presence of active Cdh1.
CycB is required to initiate DNA replication. Cdh1 is abundant in the early G1 phase. Cyclindependent kinase inhibitor (CKI), which is also abundant in the early G1 phase keeps small
amount of active CycB inactive. As cell mass increases, it results in an increased rate of
formation of starter kinase (SK) transcription factor, TF. This in turn results in an increase of
starter kinase, SK. The starter kinase causes the CKI to be phosphorylated and degraded driving
the equilibrium between CKI, CycB and the Trimer (which is actually a dimer of Cdk/CycB and
CKI) towards free CycB. Free CycB phosphorylates CKI and inactivates Cdh1 thus further
increasing the CycB concentration and activates degradation of TF causing the concentration of
the starter kinase to drop. CycB activates the synthesis of Cdc20 in its inactive form. Cdc20 is a
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Figure D1: Reaction network of budding cell cycle model. Active compounds are shown as
circles or large pie pieces, inactive compounds as start and degraded compounds as small pieces.
Reactions are shown by solid arrows, activation by broken arrows. (Hjortso, unpublished work)
protein that activates degradation reaction of CycB and also activates Cdh1 from its inactive state
thus driving the cell towards division. Finally, CycB causes phosphorylation of intermediary
enzyme, IE, leading to the formation of IEP (P for phosphorylation) which activates Cdc20. As
CycB drops below a threshold value, the cell divides and will return to the initial state with low
CycB and high Cdh1, required for starting another cell division cycle.
The model is formulated in the same way as the four component model presented earlier
using stochastic kinetics approach. Various variables in the model are listed in the Table 1. The
variables are the number of molecules of the different molecular species of the reaction network
and the continuous variable, cell mass. The molecular species are all represented by non-negative
integer values.
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Table D1: List of variables in the model. Intermediary enzyme, IE is not used in the model
explicitly
Postion

Species
symbol
SK

1

Starter kinase. Dimer of Cdk, called Cln2 in budding yeast, Cig2 in fission
yeast and Cyclin D in vertebrates.
TF
Transcription factor for SK
CKI
Cyclin-dependent kinase inhibitor. Binds to Cycb to form Trimer. A quasi
steady state equilibrium is assumed between this compound, CycB and
Trimer.
CycB
S-G2-M phase cyclin. Binds to CKI to form Trimer. A quasi steady state
equilibrium is assumed between this compound, CKI and trimer.
Cdh1
The active or unphosporylated form of Cdh1
Cdc20I Inactive form of Cdc20
Cdc20A active form of Cdc20
IEP
Active form of intermediary enzyme
Trimer Compound formed when CKI binds to CycB (which more accurately is a
dimer of CyclinB and Cdk. Thus the ame trimer). A quasi steady state
equilibrium is assumed between CKI, CycB and trimer.
m
Cell mass

2
3

4
5
6
7
8
9

10

The cell cycle network is converted into a set of biochemical reactions associated with
propensities which is shown in Table D2.
Table D2: List of reactions in the 10 component model
Reaction
Number
1
2

3
4

Description

Stoichiometry

Constant rate of
formation of CycB:
Degradation of
CycB. Three first
order mechanisms:
Unactivated,
activated by cdh1
and activated by
Cdc20A
Formation and
activation of Cdh1

Propensity, Cn

hn
1

1

Inactivation, i.e.
phosphorylation of
Cdh1
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5

Formation and
inactivation of
Cdc20

6

Degradation of
inactivation of
Cdc20
Formation of active
Cdc20 from
inactive Cdc20

7

8

1

10

Formation of active
Cdc20 from
inactive Cdc20
from active Cdc20
Formation of active
IEP
Inactivation of IEP

11

Formation of CKI

1

12

[

13

Degradation of CKI
through three first
order mechanism
Formation of SK

14

Degradation of SK

[SK]

15

Formation of TF

1

16

Degradation of TF

17

Degradation of
active Cdc20

9

1

1

CycB, CKI and Trimer are assumed to be in equilibrium and this is incorporated by the
quasi-steady state assumption which is handled as follows. Suppose that at t0, a reaction occurs
that changes the number of molecules of CKI and CycB. After this reaction has occurred, the
state of the system is given by the molecular numbers
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,
which obviously do not satisfy the equilibrium assumption. The molecular numbers after
equilibrium has been attained are determined from the equilibrium equation and two
stoichiometric balances

which have the solution

=
=
where

The solution for the number of molecular species obtained from the above relation is not
an integer. One approximation included is rounding off the solution to the nearest integer. This is
obviously incorrect since the species involved in the quasi-steady state equilibrium must satisfy
some probability distribution according to the chemical master equation. As a first step, model is
simulated using this approximation.
The parameter values used in the simulation are shown in Table D3. The simulation of
the cell cycle model using Gillespie‟s algorithm resulted in cell cycle oscillations and one such
result showing the time course trajectories of different state variables including the cell mass is
shown in Fig. D2.
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Table D3: Parameter values and Trigger values used in the simulations
Parameter and Trigger Values for the 10 component
model
k1
250
k15_11
5
k2_1
0.1
k16_1
0.1
k2_11
10
k16_11
1000
k2_111
0.1
k17
0.1
k3_1
0.1
Keq
0.7
k3_11
100
k4_1
80
J3
10
k4_11
20
J4
10
k5_1
0.1
J5
500000
k5_11
0.1
J7
100
k6
0.1
J8
100
k7
100
J15
100
k8
500
J16
1
k9
100
n
5
k10
100
k11
300
Trigger Values
k12_1
0.1
Start_Trigger
30
k12_11
20
Division_Trigger
25
k12_111
0.1
m_death
5
k13_1
5
k13_11
150
nu
1
k14
500
min_mass
0.2
k15_1
10000
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Figure D2: Cell cycle oscillations from the 10 component model using quasi-steady state
approximation
D.2. Insilico evolution of 10 component model
The insilico evolution simulations are run for two cases for the 10 component model with the
quasi-steady state assumption described earlier.


Binary fission, with mother and daughter getting same mass at the time of division



A more refined approach where mother attains a mass close to critical cell mass and
daughter gets the remaining. Start event will not occur until, the cell mass reaches a value
equal to the critical cell mass

Simulation results for the case of unequal division for a mutation rate of 0.2 are presented in Fig.
D3.
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Figure D3: Insilico evolution simulations for the 10 component model
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(Figure D3 continued)

General observations from the simulations are


There is no convergence in the cell mass



The average number of trimer molecules is continuously increasing with each iteration



Execution times have increased drastically with the number of iterations



Some of the parameters have approached values close to zero and some have moved
towards very high values



Starter Kinase (SK) molecules kept on increasing as the number of iterations in the
insilico evolutions has increased.
The rate parameters corresponding to the formation, degradation of TF for the SK and

also, the formation of SK reaction have attained very high values (Reactions 15, 16, 13
respectively). This resulted in very high values for the number of starter kinase (SK) molecules
as the iterations are continued longer and the execution time of the algorithm also increased
proportionately.
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The insilico evolution results did not give any convergence values for cell mass. The only
change observed is the increase in the parameters corresponding to the formation and
degradation of SK, TF.
The results of the cell cycle model are analyzed and it is observed that the number of
trimer molecules in a cell have gradually increased as the number of cell divisions increased for
the same set of parameters and also cell mass has increased.
It is suspected that the problem might be in the quasi-steady state assumption.
Hence, the handling of QSSA in the model is reconsidered.
D.3. Original Stochastic Algorithm and Simulation of the 10 Component Model
The equilibrium reaction is re-written as two separate reactions and the resulting reaction
set is simulated using stochastic simulation algorithm of Gillespie with high propensity values
for the two equilibrium reactions. Hence, the two reactions corresponding to the equilibrium
occur very fast and thus have the chance of being fired frequently than the other reactions which
are slow reactions. However, the dynamics of the system can be described only if large numbers
of slow reactions have occurred.
As expected, the computational time is wasted by simulating the fast reactions most
frequently and the simulations took long time to obtain the time course of different cell cycle
proteins. The two additional reactions along with their propensities are shown in the Table D4.
The resulting cell cycle oscillations are shown in the Fig. D4.
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Table D4: Two reactions added to the stochastic chemical kinetic model, by avoiding the quasisteady state assumption
Reaction
Number
18
19

Description

Stoichiometry

Formation of
Trimer
Dissociation of
Trimer

Propensity, Cn

hn

k18
k19

Figure D4: the simulation results for the 19 reactions. The execution time is 80832 sec for three
completed cell cycles. (10 time units in the model)
D.4. Slow Scale Stochastic Simulation
It is thought that the QSSA assumption needs to be reconsidered. Cao et al. (2005)
proposed a slow-scale stochastic simulation approach to handle the reactions involving slow and
fast reactions occurring on widely different time scales. The description of the approach and its
application to the 10 component model is presented here.
The reactions are classified into slow and fast reactions depending on the reaction
propensities. The reactions for which propensities are usually much larger than those the other
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reactions are fast reactions and the rest are slow reactions. Reacting species are also classified as
slow and fast. Any species whose population gets changed by the occurrence of fast reaction is
defined as fast species and the species that does not get changed by the fast reaction is defined as
slow species.
The fast and slow reaction propensity functions depend in general on both the fast and
slow species which are represented as:

is the generic representation of the state of the system which contains slow (
fast variables (

) variables and

).

is the number of fast reactions and

is the number of slow reactions.

According to slow-scale SSA, if two conditions are satisfied, the state of the system evolution
can be described in terms of the occurrence of slow reactions alone. Those are,


The time scales of fast reactions are very small compared to the time scales of slow
reactions. Then, a large number of fast reactions occur between two successive slow
reactions.



The fast variables reach a steady state between the occurrence of two slow reactions.
When a slow reaction occurs, state of the system is updated and this change in the state of
the system affects the propensities of fast reactions. As a result, many fast reactions occur
and generally, a stable state is reached before another slow reaction occurs.
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If the above conditions are satisfied, slow reactions and fast reactions can be considered
as two discreet markov processes occurring on different time scales.
Fast reactions follow a discreet markov process with slow reactions turned off. The stable
state of the system after a series of fast reactions is obtained by solving the steady state CME.
Steady state solutions of CME are available for simple reactions as described in McQuarre
(McQuarre, 1967).
The slow reactions also follow a discreet markov process. The propensities required for
simulating the slow reactions are calculated based on the weighted average of the propensities of
the steady state distribution of states obtained from the solution of CME for fast reactions.
D.5. Application of the Slow-Scale SSA to the Ten Component Model
The steps of the algorithm are explained by using the example of the 10 component model.
1. Initialize the state of the system as

in terms of fast and slow variables.

For the 10 component model,

2. Calculate the propensity function

for each slow reaction (

the average of the regular propensity functions of

).

is

over the distribution of the fast

variables obtained from the steady state CME of the fast reactions.

is the steady state probability distribution of the fast variables, when the system is initially in
the state

. This distribution can be derived for trivial systems.
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For the present equilibrium reaction,

, is the equilibrium constant of the dimerization reaction.

are the equivalent

forward and reverse rate constants for the dimerization reactions.
The probability distribution is derived by solving the steady state master equation.

are the initial state of the fast variables,

respectively, from which

final steady state distribution of the state is evaluated from the steady state CME of fast
reactions.

is the equilibrium constant of the dimerization reaction.

is the probability of finding „ ‟ number of molecules of CycB when the state of the system is
evolving from the initial state (

) according to the CME of the equilibrium dimerization

reaction.

is the maximum number of molecules of CycB that can be observed for the given initial state.

The other fast variables are calculated from the stoichiometric relations,
[

3. The next slow reaction (µ) and the time ( ) at which it occurs is calculated from the
average propensities of each of the slow reactions calculated in the earlier step.
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Calculate,
Generate uniformly distributed random numbers in [0,1], r1 and r2
Select

Select µ as an integer satisfying,
4. Update the system according to the occurrence of the slow reaction, µ.
5. The new state after the update,

changes the propensities of the fast reactions and

the system attains a new set of stationary values of fast variables. The new state is
selected randomly following the steady state distribution of fast variables.

Then,
6. The procedure is repeated until the end time.
In the above procedure, selecting the state of the fast variable according to the probability
distribution given by

is a difficult task.

A simplification is suggested by Cao et al. (2005) in their slow-scale SSA work. If the
distribution is unimodal, it can be represented by an equivalent normal distribution with the
mean and variance calculated from the discreet markov process representation of the fast
reactions.
The mean of the state,

Where,

is calculated as the root of the equation,

is the probability that the state will be

.
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) in the time interval

For the present system,

From the above relationships, the mean value of the final state in fast variables, starting
from the initial state

is given by,

Variance of the equivalent normal distribution is given by,

For the present case,

These expressions of mean and variance provide an approximate way to choose the stable
state of fast variables between two successive slow reactions, without using the cumbersome
probability distribution mentioned earlier.
D.5.1. Calculation of the Average Reaction Propensities for the Slow Reactions
Calculation of the weighted average of the reaction propensity function given by

Simplifications can be made for trivial reactions such as simple unimolecular, bimolecular
reactions.
When

, then
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When

, then

By knowing the first and second moments of the fast variables above expressions can be
evaluated.
The similar adjustments are made to the propensity functions of the ten component
. For example, propensity function for the 9th

model, using the mean value of CycB,
reaction in the reaction network is calculated as:

Whenever, such adjustments are not possible, a deterministic approximation is made. For
example, propensity function for 5th reaction is calculated as:

It is not quantified, how much such adjustments can induce errors in the model predictions. It is
taken as an initial approximation towards implementing the multi-scale simulation approach for
the cell cycle model.
The simulation results of the model are presented in Fig. D5.

155

Figure D5: Simulation results for the slow scale stochastic simulation approach. The execution
time is 214 sec for three completed cell cycles. (10 time units in the model). The accuracy of the
model still needs to be evaluated.
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APPENDIX E. REVIEW OF MATHEMATICAL MODELS IN CHEMOTHERAPY
There are many models described in the literature and they have different objectives and
goals in the context of chemotherapy studies. These models vary from simple tumor growth
models that focus on finding out the administration strategies without including details like
pharmacokinetics, drug resistance to complex models that follow an integrated approach with
aiming for tailoring the treatments to individuals and for in silico screening of potential drugs.
Norton and Simon (1986) developed a mathematical model assuming non-exponential
growth for tumors without considering drug resistance. They propose that the rate of regression
of tumor is proportional to the growth fraction of an unperturbed tumor of the same size and
conclude that the dose of the drug should be intensified as the size of the tumor decreases. This
concept of late intensification is well known as the Norton and Simon Hypothesis. Jansson
(1975) (Jansson, 1975) developed cell cycle phase specific model that includes cell
differentiation and heterogeneity with capability to obtain growth dynamics of cancer cells,
normal cells in parallel with a separate use of cell cycle kinetic parameters. Through the model,
the researcher Identifies treatment protocols that show improvement for cancer reduction and
toxicity control. Webb (1990) studies the resonance phenomenon discovered by Dibrov (Dibrov
et al., 1985) considered to be significant in periodic administration of chemotherapic drugs
according to which toxicity to normal cells can be minimized by adjusting the treatment period
close to the mean cell cycle length of normal cells. An age and size structured population balance
model accounting for cell cycle variability is used for cancer cells and normal cells with different
parameters. Drug action is instantaneous and drug PD is introduced by including periodic cell
loss function that is „on-off‟ destruction of cells. Augur et al. (1988) (Agur et al., 1988) develop
a cell cycle specific model for heterogeneous cell population based on a Malthusian form
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(Sundareshan and Fundakowski, 1984) for intrinsic population growth and dividing cell cycle
into drug resistant and sensitive phases. The model based on different parameters for normal and
cancer cells evaluates periodic treatment protocols based on elimination times of both types of
cells under treatment.
Many models are described by applying optimal control theory to obtain best drug
administration profiles during the treatment period. These models focus on different objectives
such as minimizing the tumor size, maximizing the bone marrow population under treatment
constraints generally using compartmental models. A review of cell cycle non-specific models
using optimal control is presented by Swan (1990) and Swierniak et al. (Swierniak et al., 2003)
presents cell cycle specific models. Ledzewicz & Schattler (2007) derive optimal drug schedules
based on a cell cycle non-specific model to minimize the bone marrow depletion using simple
PD and PK. Ledzewicz & Schattler (2002) present a cell cycle specific model for minimizing
cancer cells at the end of the treatment. Fister and Panetta (2000) (Fister and Panetta, 2000)
apply optimal control theory to maximize both bone marrow and the amount of drug dose to kill
cancer cells using cell cycle specific three compartmental model. In the model by Dua et al.
(2008) (Dua et al., 2008), growth dynamics of both normal cells and cancer cells are described
using different growth equations and optimal control problem is formulated to minimize the total
tumor size after some time while restricting the toxicity to the normal cells. Two different
models are solved for cell cycle specific and cell cycle non-specific treatments by coupling to
PK/PD models. Ledzewicz & Schattler (2005) proposed a cycle non-specific model using a two
compartmental model to demonstrate that addition of PK/PD models does not change the optimal
solution of drug doses and scheduling. Dibrov (1985) discovered the phenomenon of resonance
in chemotherapic applications studies the phenomenon using optimal control methods through
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their age structured model for heterogeneous cell population used for both normal and cancer
cells with different model parameters. They suggest that the drug administration should be
periodic rather than continuous and also the period of drug administration should be small and
more frequent. They determine the optimum period is close to the value of the cell cycle length
when large variations exist between the normal and cancer cells.
Models are developed with the aim to determine the drug schedules to minimize the
evolving drug resistance during the treatment. (Goldie and Coldman, 1983) presented their point
mutational stochastic model for drug resistance for non cell cycle specific drugs by assuming
instantaneous action of drug. Their model considers two non-cross resistant identical drugs
which can be extended for multiple drugs. Later, Day (1986) relax the symmetry assumption for
drugs and suggest administration strategies based on a multi type branching process model (Day,
1986). These models do not consider cell cycle effects and only study chemotherapy scheduling
in the context of drug resistance. Gaffney (2004) combine cell cycle effects with drug resistance
using their age structured population balance model and suggest schedules to reduce the
probability of development of drug resistance. A branching random walk model is developed by
Kimmel and Swiernaik (2006) (Kimmel and Swierniak, 2006) in which they apply optimal
control theory for designing chemotherapic scheduling by including cell cycle effects and drug
resistance through gene amplification mechanism.
More

complex

models

include

features

like

stochasticity,

quiescence,

drug

pharmacokinetics, pharamacodynamics, drug resistance, spatial variations in a detailed
formulation, in some cases based on experimentally derived parameters. Sherer et al. (2006)
(Sherer et al., 2006) examined the resonance effect in chemotherapy using a multi-staged age
structured population balance model for cell cycle specific drugs with variable transition and
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death rates. Dividing cells into six different phases, their model is used to study the influence of
in vivo effects such as quiescence, drug metabolism, drug properties, and transport
considerations on the resonance chemotherapy.

Sherer et al. (2007) (Sherer et al., 2007),

through an age structured binary cell division population balance model, present probabilistic
interpretations for obtaining treatment durations that result in complete cancer cure. The model
considers variable response of patients to treatment and presence of dormant population while
not considering the cell cycle effects, toxicity to normal cells and drug pharmacokinetics.
Another model (Coldman and Murray, 2000) applies optimal control techniques to consider
multiple determinant of chemotherapy – toxicity, drug resistance, tumor control, which are
separately handled separately by many other optimal control models. A birth and death type of
stochastic model is used neglecting PK/PD effects. Model by Panetta et al. (2008) (Panetta et al.,
2008) combines PK/PD models with models for cancer growth and neutrophil production in the
bone marrow to demonstrate its usefulness in the clinical practice. Based on the experimentally
derived parameters, they aim to identify the schedules and exposure times for improved tumor
response with minimized toxicities. In another study (Stamatakos et al., 2006), a spatiotemporal
Monte Carlo simulation model of tumor response to chemotherapy is developed based on three
dimensional structural and functional information from tumors of individual patients. Toxicity
and drug resistances are neglected.
An integrative approach that combines different modules at different scales for
chemotherapy studies will be useful for predicting invivo tumor growth and response to
chemotherapy and thus helpful in achieving the much desired goals of cancer research
community – for screening potential drugs in silico and for tailoring treatments to individual
patients. Sanga et al. (2006) described the framework for development of such a simulator that
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integrates tumor growth in spatial domain, tumor induced angiogenesis, drug resistance, PD and
PK that is suitable for application of multiple drugs. Venkatasubramanian (2008) developed an
integrated model where cell cycle transitions are described based on energy metabolism and
spatial heterogeneity of tumor is considered. Neglecting toxicity, drug resistance their integrated
model studies the effect of PK, PD on treatment efficacy. (Kolokotroni, 2008) describe a multiscale spatiotemporal, patient specific model that integrates PK, PD and cell cycle kinetics by
considering different types of cells such as stem cells, cells with limited mitotic capability,
differentiated cells, necrotic cells, dead cells. Their model based on the data from individual
patients is aimed at translating the integrated model into clinical practice for optimizing cancer
treatment in the patient individualized context.
Another model that has integrated many modules of integrated chemotherapy model
framework is OncoTCap (Oncology Thinking Cap) developed by Day and colleagues (Day R,
1998; Gardner and Fernandes, 2003). This simulation tool, developed based on the multi-type
branching process model by (Day, 1986), is capable of describing phenomena such as
heterogeneity in cell kinetics, random mutations, cell death due to chemotherapic treatment, drug
resistance, quiescence, stem-cell differentiation, metastasis, spatial heterogeneity and gene
amplification, however with the high dependence on computational power. The model derives a
cumulative probability generating function of different types of cells which can be used to find
out the probability of cure of a given treatment, effect of different treatment schedules on the
heterogeneous cell population. However, drug action is assumed to be instantaneous and cell
cycle specificity, drug pharmacokinetics are neglected. OncoTCap simulation tool was used for
educating medical students about clinical trials (Day et al., 2004). In another study, Gardner
(2002) develop an integrated model, Kinetically Tailored Treatment (KITT), that includes
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exponential and gompertzian growth, drug resistance, multi drug testing capability, PK,PD, intratumor heterogeneity, apoptosis, quiescence based on experimentally derived parameters. The
same model can be used for tumor cells and for different types of normal cells accounting for
toxicities, by using different parameters. The model is demonstrated to tailor the treatments to
individuals when combinations of cell cycle specific, non-specific and cytostatic drugs are used.
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